

**This item is the archived peer-reviewed author-version of:**

Neuroimaging of subacute brain inflammation and microstructural changes predicts long-term functional outcome after experimental traumatic brain injury

**Reference:**

Missault Stephan, Anckaerts Cynthia, Blockx Ines, Deleye Steven, Van Dam Debby, Barriche Nora, De Pauw Glenn, Aertgeerts Stephanie, Valkenburg Femke, De Deyn Peter Paul, ...- Neuroimaging of subacute brain inflammation and microstructural changes predicts long-term functional outcome after experimental traumatic brain injury

Journal of neurotrauma - ISSN 0897-7151 - 35(2018)21 p.

Full text (Publisher's DOI): <https://doi.org/10.1089/NEU.2018.5704>

To cite this reference: <https://hdl.handle.net/10067/1529590151162165141>

1 **Neuroimaging of subacute brain inflammation and microstructural changes predicts**  
2 **long-term functional outcome after experimental traumatic brain injury**

3 *Stephan Missault<sup>1,2</sup>, Cynthia Anckaerts<sup>2</sup>, Ines Blockx<sup>2</sup>, Steven Deleye<sup>3</sup>, Debby Van Dam<sup>4</sup>,*  
4 *Nora Barriche<sup>1</sup>, Glenn De Pauw<sup>1</sup>, Stephanie Aertgeerts<sup>1</sup>, Femke Valkenburg<sup>4</sup>, Peter Paul De*  
5 *Deyn<sup>4</sup>, Jeroen Verhaeghe<sup>3</sup>, Leonie wyffels<sup>3,5</sup>, Annemie Van der Linden<sup>2</sup>, Steven Staelens<sup>3</sup>,*  
6 *Marleen Verhoye<sup>2</sup>, Stefanie Dedeurwaerdere<sup>6,#</sup>*

7 *<sup>1</sup>Experimental Laboratory of Translational Neuroscience and Otolaryngology, Faculty of*  
8 *Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk,*  
9 *Belgium. <sup>2</sup>Bio-Imaging Lab, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences,*  
10 *University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. <sup>3</sup>Molecular Imaging*  
11 *Center Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp,*  
12 *Universiteitsplein 1, 2610 Wilrijk, Belgium. <sup>4</sup>Laboratory of Neurochemistry and Behaviour,*  
13 *Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium;*  
14 *Department of Neurology and Alzheimer Research Center, University of Groningen and*  
15 *University Medical Center Groningen (UMCG), Groningen, The Netherlands. <sup>5</sup>Department*  
16 *of Nuclear Medicine, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium.*  
17 *<sup>6</sup>Laboratory of Experimental Hematology, Faculty of Medicine and Health Sciences,*  
18 *University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. <sup>#</sup>Current address:*  
19 *UCB Biopharma S.P.R.L., Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.*

20 **Corresponding author:**

21 Stephan Missault: T +32 3 265 8818; stephan.missault@uantwerpen.be

22 **Running title (<45 characters):** TSPO PET and DTI predict chronic TBI outcome

- 23 **Table of Contents title (<75 characters):** Subacute inflammation and DTI metrics correlate  
24 with chronic outcome of TBI
- 25 Stephan Missault, PhD: T +32 3 265 8818; [stephan.missault@uantwerpen.be](mailto:stephan.missault@uantwerpen.be)
- 26 Cynthia Anckaerts, MSc: T +32 3 265 2243; [cynthia.anckaerts@uantwerpen.be](mailto:cynthia.anckaerts@uantwerpen.be)
- 27 Ines Blockx, PhD: [iblockxx@gmail.com](mailto:iblockxx@gmail.com)
- 28 Steven Deleye, PhD: [steven\\_deleye@hotmail.com](mailto:steven_deleye@hotmail.com)
- 29 Debby Van Dam, PhD: T +32 3 265 2643; [debby.vandam@uantwerpen.be](mailto:debby.vandam@uantwerpen.be)
- 30 Nora Barriche, MSc: [norabarriche@msn.com](mailto:norabarriche@msn.com)
- 31 Glenn De Pauw, MSc: [glenn.depauw17@gmail.com](mailto:glenn.depauw17@gmail.com)
- 32 Stephanie Aertgeerts, MSc: [stephanie.aertgeerts.sa@gmail.com](mailto:stephanie.aertgeerts.sa@gmail.com)
- 33 Femke Valkenburg, MSc: T +32 3 265 2678; [femke.valkenburg@uantwerpen.be](mailto:femke.valkenburg@uantwerpen.be)
- 34 Peter Paul De Deyn, PhD: T +32 3 265 2620; [peter.dedeyn@uantwerpen.be](mailto:peter.dedeyn@uantwerpen.be)
- 35 Jeroen Verhaeghe, PhD: T +32 3 265 2818; [jeroen.verhaeghe@uantwerpen.be](mailto:jeroen.verhaeghe@uantwerpen.be)
- 36 Leonie wyffels, PhD: T +32 3 821 5699; [leonie.wyffels@uza.be](mailto:leonie.wyffels@uza.be)
- 37 Annemie Van der Linden, PhD: T +32 3 265 2775; [annemie.vanderlinden@uantwerpen.be](mailto:annemie.vanderlinden@uantwerpen.be)
- 38 Steven Staelens, PhD: T +32 3 265 2820; [steven.staelens@uantwerpen.be](mailto:steven.staelens@uantwerpen.be)
- 39 Marleen Verhoye, PhD: T +32 3 265 2786; [marleen.verhoye@uantwerpen.be](mailto:marleen.verhoye@uantwerpen.be)
- 40 Stefanie Dedeurwaerdere, PhD: [stefanie.dedeurwaerdere@ucb.com](mailto:stefanie.dedeurwaerdere@ucb.com)
- 41

42 **Abstract (<250 words)**

43 There is currently a lack of prognostic biomarkers to predict the different sequelae following  
44 traumatic brain injury (TBI). The present study investigated the hypothesis that subacute  
45 neuroinflammation and microstructural changes correlate with chronic TBI deficits. Rats were  
46 subjected to Controlled Cortical Impact (CCI) injury, sham surgery or skin incision (naïve).  
47 CCI-injured (n=18) and sham-operated rats (n=6) underwent positron emission tomography  
48 (PET) imaging with the translocator protein (TSPO) radioligand [<sup>18</sup>F]PBR111 and diffusion  
49 tensor imaging (DTI) in the subacute phase (≤3 weeks post-injury) to quantify inflammation  
50 and microstructural alterations. CCI-injured, sham-operated and naïve rats (n=8) underwent  
51 behavioural testing in the chronic phase (5.5-10 months post-injury): open field and sucrose  
52 preference tests, two one-week video-EEG monitoring periods, pentylenetetrazole seizure  
53 susceptibility tests, and a Morris water maze test. *In vivo* imaging revealed pronounced  
54 neuroinflammation, decreased fractional anisotropy and increased diffusivity in perilesional  
55 cortex and ipsilesional hippocampus of CCI-injured rats. Behavioural analysis revealed  
56 disinhibition, anhedonia, increased seizure susceptibility and impaired learning in CCI-injured  
57 rats. Subacute TSPO expression and changes in DTI metrics significantly correlated with  
58 several chronic deficits (Pearson's  $|r| = 0.50-0.90$ ). **Certain specific PET and DTI parameters**  
59 **had good sensitivity and specificity (area under the ROC curve=0.85-1.00) to distinguish**  
60 **between TBI animals with and without particular behavioural deficits.** Depending on the  
61 investigated behavioural deficit, PET or DTI data alone, or the combination, could **very well**  
62 predict the variability in functional outcome data (**adjusted R<sup>2</sup>=0.54-1.00**). Taken together, both  
63 TSPO PET and DTI seem promising prognostic biomarkers to predict different chronic TBI  
64 sequelae.

65 **Key words (<5):** positron emission tomography, diffusion tensor imaging, posttraumatic  
66 epilepsy, TSPO PET, MRI

## 68 **Introduction**

69 Traumatic brain injury (TBI) is a major public health and socioeconomic problem, which  
70 affects all ages and populations throughout the world. TBI is defined as any kind of brain injury  
71 due to external force and is a leading cause of mortality and morbidity worldwide. It is  
72 commonly referred to as a silent epidemic, partly due to the public unawareness of the major  
73 long-lasting consequences that can occur following TBI including posttraumatic epilepsy,  
74 cognitive problems and psychiatric deficits.<sup>1, 2</sup> Prognostic models have been developed to  
75 predict the outcome following TBI, but a major limitation in the construction of these models  
76 was that they only used mortality and unfavourable outcome (dead, vegetative state and severe  
77 disability) as possible outcomes, while the prediction of the different sequelae that can develop  
78 following TBI remains unaddressed.<sup>3, 4</sup> This dichotomisation evidently leads to a loss of  
79 information and a reduced sensitivity of the prognostic models.<sup>5</sup> Moreover, these models use  
80 rather unspecific predictors such as age, motor score, and pupillary reactivity.<sup>3, 4</sup> A more  
81 comprehensive approach to identify specific predictors may be to investigate the link between  
82 a potential prognostic biomarker that is linked to the underlying neurobiological response to  
83 TBI and the development of chronic deficits. Moreover, while the existing prognostic models  
84 have been shown to be of value for the classification of patients, great caution is required when  
85 applying them to determine the individual risk of a single patient.<sup>6</sup> The identification of specific  
86 prognostic biomarkers would be of major value to identify patients that will develop a certain  
87 chronic consequence. Additionally, they might provide insight into the underlying  
88 neurobiological mechanisms that give rise to the TBI-related sequelae and open new avenues  
89 towards treatment and possibly prevention of these secondary consequences.

90 Inflammation is a very important secondary injury mechanism in TBI. Upon initial injury, a  
91 neuroinflammatory response is elicited, which involves both resident and peripheral immune  
92 cells. This response is complex and can have both beneficial and detrimental consequences for

93 the neurons, depending on the timing and the cell types involved, as well as the molecular  
94 context in which they act.<sup>7, 8</sup> Several inflammatory mediators have been demonstrated to  
95 exhibit epileptogenic and ictogenic properties and might be involved in the development of  
96 posttraumatic epilepsy.<sup>7</sup> Neuroinflammation has also been demonstrated to play an important  
97 role in cognitive dysfunction and psychiatric deficits following TBI. Inhibition of (sub)acute  
98 microglial activation and suppression of (sub)acute release of proinflammatory cytokines and  
99 chemokines has been shown to improve the cognitive outcome following experimental TBI.<sup>9-</sup>  
100 <sup>11</sup> Acute inflammatory biomarker profiles in cerebrospinal fluid of TBI patients have been  
101 shown to predict the risk for developing depression.<sup>12</sup> Evidence suggests that TBI induces  
102 microglial priming, which renders microglia more susceptible to a secondary inflammatory  
103 stimulus. An exaggerated inflammatory response to a secondary insult has been shown to  
104 concur with cognitive impairment and depressive behaviour.<sup>13, 14</sup>

105 Positron emission tomography (PET) radioligands that bind to the translocator protein 18 kDa  
106 (TSPO), which is highly upregulated on the outer mitochondrial membrane of activated  
107 microglia (amongst other cell types), are ideally suited to assess brain inflammation *in vivo* and  
108 to investigate whether early inflammation following brain insults can act as a prognostic  
109 biomarker for the long-term functional outcome. We have recently shown that *in vivo*  
110 assessment of TSPO expression in the early phase following *status epilepticus* could predict  
111 the frequency of chronic spontaneous recurrent seizures and behavioural comorbidities in a rat  
112 model of temporal lobe epilepsy.<sup>15</sup> Few *in vivo* imaging studies with TSPO radioligands have  
113 been performed in TBI models. Wang et al. reported a peak in TSPO ligand binding at 6 days  
114 after controlled cortical impact (CCI) injury, which decreased gradually to near normal levels  
115 at 28 days post-injury.<sup>16</sup> Yu et al. also observed a peak in TSPO ligand binding at 1 week after  
116 fluid percussion injury, which decreased during the next eight weeks of observation.<sup>17</sup>

117 **However, a limitation of TSPO is the lack of cell specificity. While TSPO is highly expressed**

118 by activated microglia, it is also upregulated in other activated immune-competent cells,  
119 including macrophages, astrocytes, neutrophils and lymphocytes.<sup>16-18</sup> While several studies in  
120 TBI animal models pointed to microglia/macrophages as the main cellular sources of the TSPO  
121 signal with an additional contribution of astrocytes, a contribution of neutrophils and  
122 lymphocytes cannot be excluded.<sup>16, 17, 19</sup>

123 Diffusion imaging has emerged as a very powerful tool to characterise microstructural changes  
124 in both grey and white matter following TBI. Both diffusion-weighted imaging (DWI) and  
125 diffusion tensor imaging (DTI) have been proven to be highly sensitive techniques to assess  
126 alterations in tissue microstructure and diffuse axonal injury after TBI.<sup>20-23</sup> The average  
127 diffusion (average of three diffusion coefficients in three orthogonal directions) has been  
128 investigated as a potential prognostic biomarker of the long-term functional outcome following  
129 experimental TBI. Kharatishvili et al. showed that average diffusion in the ipsilesional  
130 hippocampus at both early and chronic time-points following lateral fluid percussion injury  
131 (FPI) correlated with pentylenetetrazole (PTZ)-evoked seizure susceptibility at 12 months  
132 post-injury.<sup>24</sup> In an extended reanalysis of these data, Immonen et al. observed that average  
133 diffusion in the perilesional cortex and thalamus at 2 months post-injury showed the highest  
134 predictive value for increased seizure susceptibility at 12 months post-injury.<sup>25</sup> In another study  
135 from Immonen and colleagues it was demonstrated that average diffusion in the ipsilateral  
136 hippocampus at 23 days following FPI correlated with Morris water maze performance at 7  
137 months post-TBI.<sup>26</sup> Frey et al. showed that the (sub)acute apparent diffusion coefficient (DWI  
138 in one direction) in injured cortex after FPI correlated with chronic kainate-evoked seizure  
139 susceptibility.<sup>27</sup> Several clinical studies also indicate that DTI can be useful for the prognosis  
140 of TBI (reviewed in <sup>20</sup>).

141 Bigger lesion volumes, determined by T<sub>2</sub>-weighted MRI, have been shown to be associated  
142 with a poorer outcome after TBI.<sup>28</sup>

143 In this study we have first of all investigated whether i) subacute brain inflammation, assessed  
144 by *in vivo* PET imaging with the TSPO ligand [<sup>18</sup>F]PBR111, ii) subacute microstructural  
145 changes, assessed by *in vivo* DTI, and iii) subacute lesion volume, assessed by T<sub>2</sub>-weighted  
146 MRI, correlated with the different chronic sequelae that may occur following TBI, including  
147 psychiatric deficits, spontaneous recurrent seizures, increased seizure susceptibility and  
148 visuospatial learning and memory deficits. Next, we have evaluated the sensitivity and  
149 specificity of these parameters in distinguishing between TBI animals with and without  
150 particular deficits. Finally, we have investigated whether PET data, DTI data or lesion volume  
151 alone, or the combination of these assessments, could best predict the variability in the different  
152 functional outcome parameters.

153



## 154 **Materials and methods**

### 155 **1. Animals**

156 Eighty-four male Sprague-Dawley rats were purchased from Envigo (previously Harlan  
157 Laboratories), the Netherlands. Animals were group-housed in a temperature- and humidity-  
158 controlled room on a 12 hour light-dark cycle with standard food and water available *ad libitum*  
159 until the moment of electrode implantation. From this point onward, animals were single-  
160 housed. Animals were treated in accordance with the EU directive 2010/63/EU. Animal  
161 experiments were approved by the animal ethics committee of the University of Antwerp,  
162 Belgium (ECD 2012-62).

### 163 **2. Study design**

164 There were in total three cohorts of animals in this study. The first and main cohort (cohort 1)  
165 included animals that were subjected to subacute *in vivo* imaging and chronic behavioural  
166 testing and EEG monitoring following experimental TBI (CCI-injury). The second cohort of  
167 animals (cohort 2) was subjected to an open field test and seizure susceptibility test in the  
168 chronic period to confirm observations that were made in the first cohort of animals. The third  
169 cohort of animals (cohort 3) was sacrificed in the subacute period for histological purposes.

170 The study design of the longitudinal *in vivo* imaging and behavioural study (cohort 1) is shown  
171 in Figure 1. A total of eight naïve, seven sham-operated and 19 CCI-injured rats were initially  
172 included in this cohort. Six sham-operated and 18 CCI-injured rats were subjected to *in vivo*  
173 imaging (PET/CT and MRI) in the subacute phase following TBI. Naïve animals were not  
174 subjected to *in vivo* imaging. PET/CT imaging was performed at 7 and 21 days post-injury and  
175 MRI at 4 and 18 days post-injury. One sham-operated rat and one CCI-injured rat were scanned  
176 at the first time-point, but died before the second time-point. This sham-operated rat was

177 included in the PET and DTI analysis to investigate differences in TSPO expression and DTI  
178 metrics between CCI-injured and sham-operated rats. The CCI-injured rat, however, died  
179 during the first PET/CT scanning session and was therefore excluded from the entire study (see  
180 below). Eight naïve, six sham-operated and 18 CCI-injured rats (including all rats that had  
181 undergone *in vivo* imaging in the subacute phase) underwent behavioural testing in the chronic  
182 period (5.5-10 months post-injury). One sham-operated rat exhibited significantly enlarged  
183 ventricles and aberrant behaviour compared to the other sham-operated rats and was excluded  
184 from the entire study (see below). In total, 17 CCI-injured rats were used to investigate a  
185 possible relationship between early brain inflammation, microstructural changes and lesion  
186 volume and chronic behavioural deficits. Finally, some rats lost their electrode assembly during  
187 the study. EEG data from these rats were included up to the point that they lost their electrode  
188 cap.

189 Cohort 2 consisted of 9 naïve, 10 sham-operated and 10 CCI-injured rats, which were subjected  
190 to an open field test at 2 months post-injury and a PTZ seizure susceptibility assay at 6 months  
191 post-injury to corroborate observations from cohort 1.

192 Cohort 3 consisted of 4 naïve, 5 sham-operated and 12 CCI-injured rats. They were sacrificed  
193 at 7 days post-injury for histological purposes.

### 194 3. Controlled Cortical Impact-induced Traumatic Brain Injury

195 CCI-injury was performed as previously described.<sup>29</sup> Eight-week old rats (mean  $\pm$  SEM: 281  
196  $\pm$  3 g) were anaesthetised with isoflurane in oxygen (5% induction, 2.5% maintenance; Forene;  
197 Abbott, Belgium). During the surgery, the animal was kept warm by means of a temperature-  
198 controlled heating pad. A craniectomy of 5 mm diameter was performed with a trephine over  
199 the left parietal cortex (midway between bregma and lambda, bordering the lateral edge)  
200 without damaging the dura. CCI was done with the Leica Impact One device (Leica

201 Biosystems, USA) using the following parameters: flat tip of 3 mm diameter, impact angle 18°,  
202 impact velocity 4 m/s, depth of penetration 2.5 mm, dwell-time 500 ms (n = 19). After impact,  
203 the cranial window was sealed with a piece of plastic, and skin sutured. Sham-operated animals  
204 were subjected to the same surgery, but were not exposed to impact (n = 7). Since previous  
205 work has shown that craniotomised animals can display behavioural deficits compared to naïve  
206 animals, naïve rats were included in this study as well.<sup>30</sup> Naïve animals received anaesthesia  
207 and a skin incision, but no craniectomy (n = 8). Naïve rats were treated in exactly the same  
208 way as sham-operated and CCI-injured rats, but did not undergo *in vivo* imaging.

#### 209 **4. PET imaging with [<sup>18</sup>F]PBR111**

210 Radiosynthesis of the TSPO radioligand [<sup>18</sup>F]PBR111 was performed on a FluorSynton I  
211 automated synthesis module (Comcer, the Netherlands) according to Bourdier et al.<sup>31</sup> PET  
212 scans were performed on an Inveon PET/CT scanner (Siemens Preclinical Solution, USA) as  
213 previously described with a few minor modifications.<sup>15</sup> Rats were anaesthetised with isoflurane  
214 in oxygen (5% induction, 2-2.5% maintenance; Abbott, Belgium), after which  $8.6 \pm 0.4$  MBq  
215 radiotracer (molar activity:  $149.8 \pm 11.0$  GBq/ $\mu$ mol) was administered by tail vein injection in  
216 a volume of 0.5 ml. During the uptake period of 45 min, the animal remained anaesthetised  
217 and was kept warm by means of a temperature-controlled heating pad. Next, animals were  
218 subjected to a static PET scan of 15 min, followed by a 7 min CT scan. At 50 min post-injection,  
219 an arterial blood sample was collected from the tail artery for radiometabolite analysis  
220 according to Katsifis et al.<sup>32</sup> During the scanning session, breathing rate and temperature were  
221 constantly monitored (Minerve, France) and maintained within normal physiological ranges.  
222 The temperature of the animal was maintained by supplying heated air through the imaging  
223 cell. PET images were reconstructed using a 2D ordered subset expectation maximization  
224 algorithm (4 iterations, 16 subsets) after Fourier rebinning.<sup>33, 34</sup> Normalisation, dead time,  
225 random, CT-based attenuation, and scatter corrections were applied.

226 Image processing was done using PMOD v3.3 (PMOD Technologies, Switzerland). The CT  
227 images were co-registered to three-dimensional (3D) T<sub>2</sub>-weighted MR images that were  
228 acquired earlier that week (see below) by manually guided automatic rigid matching. This CT  
229 to MR transformation was used to co-register the PET images to the MR images. The following  
230 volumes of interest (VOIs) were manually drawn on each individual 3D MR scan: lesion  
231 (hyperintense on the T<sub>2</sub>-weighted MR image), perilesional cortex, contralateral cortex,  
232 ipsilesional hippocampus and contralesional hippocampus. VOI statistics in kBq/cc were  
233 generated and used to calculate the standardised uptake values (SUV: average tissue  
234 radioactivity concentration [kBq/cc] / injected dose [kBq] / body weight [g]). For correlation  
235 analyses, we also calculated the relative change in SUV over time in CCI-injured rats according  
236 to the following formula:

$$237 \quad \% \text{ change} = \left( \frac{SUV \text{ at } 21 \text{ days} - SUV \text{ at } 7 \text{ days}}{SUV \text{ at } 7 \text{ days}} \right) * 100$$

238 One CCI-injured rat died during the CT scan at the first time-point. **This rat was excluded from**  
239 **the entire study.** One sham-operated rat got an infection of the tail following the first scanning  
240 time-point and was subsequently sacrificed. These rats were not scanned at the second time-  
241 point (neither PET/CT or MRI).

## 242 **5. *In vivo* MRI: DTI and 3D T<sub>2</sub>-weighted anatomical MRI**

243 Rats were anaesthetised with isoflurane in a mixture of O<sub>2</sub> (30%) and N<sub>2</sub> (70%) (5% induction,  
244 2-2.5% maintenance; Abbott, Belgium). Breathing rate and blood oxygenation were monitored  
245 constantly using a pressure sensitive pad and a pulse oximeter (MR-compatible Small Animal  
246 Monitoring and Gating System, SA Instruments, Inc., USA), and maintained between normal  
247 physiological ranges. The temperature of the animals was monitored by means of a rectal probe

248 and maintained at  $(37 \pm 0.5)$  °C through a feedback-controlled warm air system (MR-  
249 compatible Small Animal Heating System, SA Instruments, Inc., USA).

250 Data were acquired on a 7T PharmaScan with Paravision 5.1 software using a standard Bruker  
251 crosscoil set-up with a quadrature volume coil and a quadrature surface coil designed for rats  
252 (Bruker, Germany). The rats' head was immobilised in an MR-compatible stereotaxic device  
253 using blunt earplugs and a tooth bar. Three orthogonal multi-slice Turbo Rapid Acquisition  
254 with Relaxation Enhancement (RARE) T<sub>2</sub>-weighted images were acquired to ensure consistent  
255 slice positioning between DTI data of different animals. A field map was acquired to measure  
256 field homogeneity, followed by local shimming, which corrects for the measured  
257 inhomogeneity in a rectangular volume within the brain. Coronal diffusion-weighted (DW)  
258 images were acquired with a 2-shot spin-echo echo planar imaging (SE-EPI) sequence with 60  
259 optimally spread diffusion gradient directions. Fifteen non-DW b<sub>0</sub> images (b-value 0 s/mm<sup>2</sup>; 5  
260 b<sub>0</sub> per 20 DW images) were acquired. The imaging parameters were: repetition time (TR) 7500  
261 ms, echo time (TE) 26 ms, diffusion gradient pulse duration  $\delta$  4 ms, diffusion gradient  
262 separation  $\Delta$  12 ms, b-value 800 s/mm<sup>2</sup>, 20 slices of 0.7 mm (limited to cerebrum), 0.1 mm  
263 slice gap, scan duration approx. 20 min. The FOV was (30 x 30) mm<sup>2</sup> and the matrix size  
264 [128 x 128], resulting in pixel dimensions of (0.234 x 0.234) mm<sup>2</sup>. Following DTI, a 3D  
265 RARE T<sub>2</sub>-weighted scan was acquired with the following parameters: TR 3185 ms, TE 11 ms  
266 (TE<sub>eff</sub> 44 ms), RARE factor 8, 2 averages, FOV (29.0 x 16.0 x 10.2) mm<sup>3</sup>, acquisition matrix  
267 [256 x 64 x 50], spatial resolution (0.113 x 0.250 x 0.204) mm<sup>3</sup>, scan duration approx. 45 min.

268 **DTI processing.** Image processing was performed with SPM12 in MATLAB 2014a  
269 (MathWorks, USA). First, images were realigned to correct for subject motion using the  
270 diffusion toolbox in SPM12. A rigid registration was performed between the b<sub>0</sub> images, which  
271 was followed by an extended registration taking also all DW images into account. Next, the  
272 diffusion tensor was estimated and the DTI parameter maps were computed (i.e., fractional

273 anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD)).  
274 Finally, the DTI parameter maps were smoothed in plane using a Gaussian kernel with full  
275 width at half maximum (FWHM) of twice the voxel size (FWHM (0.468 x 0.468 x 0.800)  
276 mm<sup>3</sup>). Regions of interest (ROIs) (lesion, perilesional cortex, contralateral cortex, ipsilesional  
277 hippocampus and contralesional hippocampus) were manually drawn in Amira 5.4.0 on the  
278 average b<sub>0</sub> (T<sub>2</sub>-weighted) image of each animal and then adjusted on the individual FA and  
279 MD maps to ensure exclusion of white matter and ventricles. For each ROI, the mean value of  
280 the different DTI parameters was extracted in Amira 5.4.0. For correlation analyses, the relative  
281 change in DTI metrics over time in CCI-injured rats was calculated analogous to the % change  
282 in [<sup>18</sup>F]PBR111 SUVs above.

283 **Volumetric analysis.** As mentioned above, the lesion (edema) at 4 and 18 days was manually  
284 delineated on each individual 3D T<sub>2</sub>-weighted MRI scan using PMOD v3.3. In addition, we  
285 calculated the relative change in lesion volume over time in CCI-injured rats analogous to the  
286 % change in [<sup>18</sup>F]PBR111 SUVs and DTI metrics above. These measurements were used for  
287 correlation analyses with chronic deficits.

288 One sham-operated rat exhibited significantly larger ventricles at the first scanning time-point  
289 as compared to the other sham-operated rats (significant outlier) and showed a worse  
290 performance in several behavioural assays than the other sham-operated rats. This rat was  
291 excluded from the entire study. Spontaneous congenital hydrocephalus has been reported in  
292 this and other rat strains.<sup>35</sup>

## 293 **6. Long-term outcome**

### 294 **6.1. Open field test**

295 An open field test was performed to explore the presence of anxiety or disinhibition in CCI-  
296 injured rats. Cohort 1 (which included the animals that were subjected to *in vivo* imaging) was  
297 subjected to this test at ca. 5.5 months post-injury. Cohort 2 was subjected to this test at 2  
298 months post-injury. Animals were placed in the periphery of a well-lit square arena ((48 x 48)  
299 cm<sup>2</sup>) and allowed to explore the novel environment for 10 min. During this trial, animals were  
300 video-tracked with EthoVision XT software (version 10.0, Noldus, the Netherlands). For  
301 analysis, the arena was divided in a central zone (inner square, (24 x 24) cm<sup>2</sup>) and a peripheral  
302 zone. The following parameters were calculated: latency to first entry in central zone, number  
303 of transitions from periphery to centre, % time spent in centre, % distance moved in centre,  
304 total distance moved and mean velocity.

## 305 **6.2. Sucrose preference test**

306 A sucrose preference test was done in cohort 1 at ca. 5.5 months post-injury to assess the  
307 presence of anhedonia in the CCI-injured rats. The test was performed as previously  
308 described.<sup>36</sup> Briefly, animals received two drinking bottles, one filled with water and one with  
309 2% sucrose solution. After 48 h of habituation, the % sucrose preference and total fluid intake  
310 were calculated over a test period of 24 h.

## 311 **6.3. Video-EEG: spontaneous recurrent seizures and seizure susceptibility**

312 *Electrode implantation.* All animals were implanted with six epidural screw electrodes as  
313 described before<sup>37</sup>, however, with a different positioning. One electrode was implanted rostral  
314 to the lesion over the left cortex (between bregma and lesion), two electrodes were implanted  
315 over the right cortex: one contralateral to the first electrode and the other opposite to the core  
316 of the lesion near the sagittal midline, one electrode was positioned over the left frontal lobe,  
317 and two more over the occipital lobe. Electrodes were fixed into a plastic plug (Bilaney  
318 Consultants, Plastics One, UK) and secured to the skull using dental cement (Simplex Rapid,

319 Kemdent, UK; Durelon, 3M ESPE, USA) and additional anchor screws. Animals were allowed  
320 to recover for at least one week before recording started.

321 *Recording.* **Animals from cohort 1** were subjected to continuous video-EEG (vEEG) recording  
322 for two periods of one week, once at 6 months post-injury and once at 9 months post-injury.  
323 The week of recording spontaneous epileptiform activity and seizures was each time followed  
324 by a PTZ seizure susceptibility test (see below). Animals were connected to a digital EEG  
325 acquisition system (Ponemah P3 Plus, Data Sciences International, USA) through a cable  
326 system as previously described.<sup>37</sup> EEG was recorded from the electrode rostral to the lesion  
327 and the contralateral electrode. The occipital electrodes were used as reference and ground  
328 electrodes. Due to limited capacity of the recording system, only four out of the eight naïve  
329 animals were subjected to continuous vEEG recording at the 6-month time-point. For the same  
330 reason, the CCI-injured rat and sham-operated rat that were not subjected to *in vivo* imaging  
331 did not undergo vEEG recording at this time-point. Between the 6-month and 9-month time-  
332 points, several animals lost their electrode assembly (4/8 naïve, 1/6 sham, 11/18 CCI). Hence,  
333 fewer rats underwent vEEG recording at the 9-month time-point.

334 *Analysis.* Video-EEG data were analysed manually using NeuroScore 3.0 (Data Sciences  
335 International, USA) as described before.<sup>37</sup> For the analysis of the spontaneous epileptiform  
336 activity and seizures, we quantified the number and duration of epileptiform discharges (EDs)  
337 and seizures per day, as well as the duration of all epileptiform activity (EDs + seizures) per  
338 day. An ED was defined as a high-amplitude (equalling at least two times the baseline  
339 amplitude) rhythmic discharge containing spikes and/or uniform sharp waves, lasting  $\geq 1$  s but  
340  $< 5$  s. Most of the observed events were either spike-wave discharges or high-voltage rhythmic  
341 spike discharges. A similar event that lasted  $> 5$  s was defined as a seizure. Video-analysis  
342 allowed us to classify seizures as purely electrographic events or behavioural seizures, which



343 were scored according to a modified Racine scale as described before.<sup>38</sup> In this study, rats were  
344 considered epileptic if they experienced two or more unprovoked convulsive seizures (S3-5).<sup>39</sup>

345 *PTZ-evoked seizure susceptibility test.* Animals were injected subcutaneously (s.c.) with a  
346 single subconvulsive dose (25-30 mg/kg) of PTZ, after which they underwent one hour of  
347 vEEG recording, a protocol adapted from<sup>24</sup>. For this test, we also quantified the number of  
348 spikes, in addition to EDs and seizures. We calculated the latency to first spike, first ED, first  
349 seizure (purely electrographic or behavioural) and first convulsive seizure, as well as the  
350 number of spikes, EDs, seizures (purely electrographic and behavioural) and convulsive  
351 seizures, and finally also the total duration of EDs, all seizures and convulsive seizures. At 6  
352 months post-injury, rats **from cohort 1** received 25 mg/kg PTZ (s.c.). Due to the low occurrence  
353 of convulsive seizures following this dose and previous reports in the literature that observed  
354 a more pronounced difference in the occurrence of convulsive seizures between TBI and  
355 control rats with a 30 mg/kg dose<sup>24, 40</sup>, we decided to administer 30 mg/kg PTZ (s.c.) **in cohort**  
356 **1** at 9 months post-injury. Three rats lost their electrode assembly during the PTZ tests (one  
357 CCI rat and one naïve rat at 6 months, one CCI rat at 9 months). They were excluded from the  
358 analysis of number of spikes, EDs and seizures, but included in the analysis of latency to first  
359 spike, ED and seizure (if recorded). For uniformity/standardisation, all animals received PTZ  
360 injections at both 6 and 9 months, even if the animals had previously lost their electrode  
361 assembly and no EEG recording could be obtained. However, these were not included in the  
362 analysis. **A PTZ test was also performed in cohort 2 at ca. 6 months post-injury, using the 30**  
363 **mg/kg PTZ dose.**

#### 364 **6.4. Morris water maze test**

365 Rats **from cohort 1** were subjected to a Morris water maze (MWM) test **at ca. 10 months post-**  
366 **injury** to investigate the extent of visuospatial learning and memory deficits in the CCI-injured

367 rats. The test was performed as previously described<sup>41</sup>. The experimental set-up consisted of a  
368 circular pool (150 cm diameter) filled with white opaque water (kept between 20 and 24°C),  
369 containing a submerged round platform (15 cm diameter) and surrounded by visual cues. Prior  
370 to the test, rats were dyed black with a non-toxic hair dye to provide contrast with the white  
371 pool for video-tracking purposes (EthoVision XT 10.0, Noldus, the Netherlands). The test  
372 consisted of a training period (acquisition) of eight days with the platform fixed in one place,  
373 and a probe trial (retention) during which the platform was removed from the swimming pool.  
374 Every training day consisted of four trials of maximally 120 s each, with the rat starting from  
375 a different position for each trial (15 min intertrial interval, semi-random order for each training  
376 day). If the rat could not locate the platform, it was placed on the platform for approximately  
377 10 s before being returned to its home cage. A learning curve was plotted for escape latency  
378 and path length to platform (sum of the four daily trials). In addition, we calculated the mean  
379 velocity. Four days after finishing the eight-day training period, the platform was removed and  
380 a probe trial of 100 s was performed. We calculated the % time spent in the target quadrant  
381 (i.e., the quadrant that previously contained the platform), as well as the number of crossings  
382 through the previous platform position.

## 383 **7. Histology**

### 384 **7.1. Tissue collection**

385 At 7 days post-injury, animals were sacrificed by decapitation. Brains were immediately  
386 resected and snap-frozen in ice-cold isopentane (3 minutes at -35°C) on dry ice. Brains were  
387 stored at -80°C until sectioning. Serial coronal cryosections (20 µm) were collected in triplicate  
388 at -2.92 mm from bregma (sections containing lesion core and dorsal hippocampus).

### 389 **7.2. Immunohistochemistry**

#### 390 **7.2.1. CD11b staining**

391 Tissue sections were stained for CD11b, which is expressed by microglia/macrophages.  
392 Sections were stained as described before<sup>42</sup> with a few modifications. Sections were dried at  
393 room temperature for 5 min, followed by fixation with 4% paraformaldehyde. After washing  
394 with Phosphate Buffered Saline (PBS), endogenous peroxidase and proteins were blocked with  
395 3% H<sub>2</sub>O<sub>2</sub> in dH<sub>2</sub>O for 5 min and 3% Normal Horse Serum (NHS) in PBS for 10 min. Sections  
396 were incubated overnight with mouse anti-CD11b antibody (AbD Serotec, UK; 1/1000) in  
397 antibody diluent, consisting of 0.1% Bovine Serum Albumin, 0.2% Triton X-100, 2% NHS  
398 and 1% milk powder in PBS. The following morning, sections were rinsed with PBS and  
399 incubated for 1 hour with peroxidase-conjugated donkey anti-mouse IgG antibody (Jackson  
400 ImmunoResearch Laboratories, UK; 1/500) in antibody diluent. 3,3'-diaminobenzidine was  
401 used for colorimetric detection. After 10 minutes, the reaction was stopped with dH<sub>2</sub>O, after  
402 which the sections were gradually dehydrated and coverslipped.

### 403 **7.2.2. GFAP staining**

404 Tissue sections were stained for GFAP, which is expressed by astrocytes. The staining protocol  
405 was similar to the one for CD11b staining with a few exceptions. For blocking of endogenous  
406 proteins, a solution containing 3% Normal Goat Serum (NGS), 1% milk powder and 0.2%  
407 Triton X-100 in PBS was used for 1 hour. Sections were incubated overnight with rabbit anti-  
408 GFAP antibody (Dako, Agilent Technologies, Belgium; 1/1000) in antibody diluent,  
409 containing 10% NGS and 1% milk powder in PBS. Sections were incubated with peroxidase-  
410 conjugated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories, UK; 1/500) in  
411 antibody diluent.

### 412 **7.2.3. Analysis of CD11b and GFAP staining**

413 Analysis was performed as described before.<sup>29</sup> Images were obtained with a NanoZoomer-XR  
414 slide scanner (Hamamatsu, Japan) equipped with a 20x objective and analysed with ImageJ

415 software. Images were transformed to 8-bit images and a threshold was set to select specifically  
416 stained cells from background staining. The area fraction, i.e., the % area of the region of  
417 interest (ROI) that consists of positively stained cells (microglia/macrophages or astrocytes)  
418 (as set by the threshold), was calculated for the following ROIs: perilesional and contralesional  
419 cortex, ipsi- and contralesional hippocampus. A higher area fraction reflects a higher density  
420 of CD11b-positive microglia/macrophages or GFAP-positive astrocytes in this ROI. All ROIs  
421 were outlined manually in triplicate samples.

### 422 **7.3. *In vitro* autoradiography with TSPO radioligand [<sup>3</sup>H]PK11195**

423  
424 *In vitro* autoradiography with TSPO radioligand [<sup>3</sup>H]PK11195 was performed exactly as  
425 described before<sup>37</sup> with two exceptions: sections were incubated with radiotracer for 1 hour  
426 and exposed on films for 6 weeks.

## 427 **8. Statistics**

428 Normal distribution of the data was tested using the D'Agostino-Pearson omnibus normality  
429 test. Outlier analyses were performed with the ROUT test. For the analysis of the open field  
430 test, sucrose preference test, spontaneous epileptiform activity and seizures at each time-point,  
431 seizure susceptibility tests and probe trial of the MWM test, we used Kruskal-Wallis tests to  
432 compare the three study groups (naïve, sham, CCI) and Dunn's multiple comparisons test as  
433 post-hoc test. When pooling all controls (naïve + sham), we used Mann-Whitney U tests to  
434 compare the two groups (control, CCI). For correlation analyses, we used the Pearson  
435 correlation test. Chi-square tests for trend were performed to investigate whether the  
436 occurrence of convulsive seizures in the PTZ tests was associated with injury (naïve, sham,  
437 CCI). For receiver operating characteristic (ROC) curve analysis, CCI-injured animals were  
438 divided into two groups for each behavioural outcome parameter: CCI-injured rats with and  
439 without a deficit. Depending on the nature of the response, CCI-injured rats with a value higher

440 than the mean + two standard deviations (SDs) of the naïve rats or a value lower than the mean  
441 - two SDs of the naïve rats were considered to have a deficit. Since 95% of the observations  
442 fall within the mean +/- two SDs range, there is a chance of less than 5% (corresponding to a  
443 p-value of 0.05) to identify TBI animals without a deficit as TBI animals with a deficit, i.e.,  
444 making a type I error (including false positives). These analyses were performed using  
445 GraphPad Prism 6. For the analysis of longitudinal data (PET, DTI, spontaneous epileptiform  
446 activity and seizures over time, MWM learning curves) we made use of linear mixed models  
447 in JMP Pro 13, which allowed us to take animals into account for which a data point was  
448 missing. Additionally, linear mixed models are more robust against non-normality of data than  
449 repeated-measures ANOVAs. For each data set, we fitted linear mixed models with Group  
450 (naïve/sham/CCI), Time (two time-points) and the interaction between Group and Time as  
451 fixed effects and either Subject alone (random intercept model, smaller model) or both Subject  
452 and Subject\*Time as random effects (random slope model, larger model). We tested the  
453 necessity for the random slope (Subject\*Time) with the likelihood ratio test. If the interaction  
454 between Group and Time proved to be significant, we performed the appropriate post-hoc tests.  
455 We did Student's t pairwise comparisons and corrected the p-values for the number of  
456 comparisons (Bonferroni correction). Finally, we also performed forward stepwise regression  
457 analysis in JMP Pro 13 with p-value threshold as stopping rule (prob to enter: 0.25, prob to  
458 leave: 0.1). Statistical significance was set at  $p \leq 0.05$ .

459

## 460 **Results**

### 461 **1. Subacute brain inflammation after CCI-injury**

462 Analysis of the PET scans revealed significantly higher SUVs of TSPO ligand [<sup>18</sup>F]PBR111 in  
463 the lesion (left parietal cortex, mean ± SEM volume: 16.4 ± 1.8 mm<sup>3</sup>), perilesional cortex and  
464 ipsilesional hippocampus of CCI-injured rats compared to sham-operated rats, which decreased  
465 over time (Fig.2A,B; Suppl.Fig.1). For each of these brain regions, a significant interaction  
466 between Group and Time (p≤0.01) was noted. Post-hoc testing revealed a significantly higher  
467 SUV for each of these brain regions in CCI-injured rats compared to shams at 7 days post-  
468 injury (lesion and ipsilesional hippocampus: p≤0.0001, perilesional cortex: p≤0.001). At 21  
469 days post-injury, there was still a significantly higher SUV in the ipsilesional hippocampus of  
470 CCI-injured rats vs. shams (p≤0.01), but the difference was smaller than at 7 days post-injury.  
471 In the other brain regions, no significant difference was present anymore at 21 days post-injury.  
472 There was a significant decrease in SUVs between 7 days and 21 days post-injury in the lesion,  
473 perilesional cortex and ipsilesional hippocampus of CCI-injured rats (p≤0.0001), while in  
474 sham-operated rats there was no change in SUV over time. No significant difference in SUVs  
475 between CCI-injured and sham-operated rats was observed at any time-point in contralateral  
476 brain regions.

477 Radiometabolite analysis revealed no significant difference in metabolisation of the radiotracer  
478 between sham-operated and CCI-injured rats (respectively, (14.4 ± 0.9)% and (15.6 ± 1.0)%  
479 intact tracer in plasma at 50 min post-injection).

### 480 **2. Histology confirms gliosis in the subacute phase following CCI-injury**

481 **The area fraction of CD11b-positive staining was significantly higher in the perilesional cortex**  
482 **and ipsilesional hippocampus of CCI-injured rats compared to both naïve and sham-operated**

483 rats at 7 days post-injury ( $p \leq 0.01$ ). There was no significant difference in the area fraction of  
484 CD11b-positive staining in the contralesional cortex and hippocampus of the three groups  
485 (Suppl.Fig.2).

486 The area fraction of GFAP-positive staining was significantly higher in the perilesional cortex  
487 of CCI-injured rats compared to both naïve and sham-operated rats at 7 days post-injury  
488 (respectively  $p \leq 0.05$  and  $p \leq 0.01$ ). The area fraction of GFAP-positive staining was also  
489 significantly higher in the ipsilesional hippocampus of CCI-injured rats compared to naïve rats  
490 ( $p \leq 0.05$ ). There was no significant difference in the % area of GFAP-positive staining in the  
491 contralesional cortex and hippocampus of the three groups (Suppl.Fig.3).

492 Qualitative comparison of TSPO *in vitro* autoradiographs, CD11b- and GFAP-stained tissue  
493 sections from the same CCI-injured animals shows that the CD11b staining pattern matches  
494 the TSPO binding pattern more closely than the GFAP staining pattern does at this time-point  
495 (Suppl.Fig.4).

### 496 **3. Subacute microstructural alterations after CCI-injury**

497 After CCI-injury, fractional anisotropy (FA) was decreased in the lesion, perilesional cortex  
498 and ipsilesional hippocampus at 4 days post-injury compared to shams. At 18 days post-injury,  
499 FA was significantly decreased in the lesion, but not in any other brain region (Fig.3A,B;  
500 Suppl.Fig.5A). Linear mixed model analysis showed a significant effect of Group on FA in the  
501 lesion ( $p \leq 0.0001$ ), while in the perilesional cortex and ipsilesional hippocampus, a significant  
502 interaction between Group and Time (respectively  $p \leq 0.0001$  and  $p \leq 0.05$ ) was present. Post-  
503 hoc analysis showed a significant difference between sham-operated and CCI-injured rats at 4  
504 days post-injury in perilesional cortex ( $p \leq 0.0001$ ) and ipsilesional hippocampus ( $p \leq 0.05$ ). In  
505 addition, there was a significant difference between 4 and 18 days in CCI-injured rats in the  
506 perilesional cortex ( $p \leq 0.0001$ ) and ipsilesional hippocampus ( $p \leq 0.05$ ). Finally, there was also

507 an effect of time on FA in contralateral cortex ( $p \leq 0.05$ ) (Suppl.Fig.5A). No significant effect  
508 of Group or Time on FA was noted in the contralesional hippocampus (Suppl.Fig.5A).

509 After CCI-injury mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD)  
510 were increased in the lesion, perilesional cortex and ipsilesional hippocampus vs. shams, which  
511 was more pronounced at the later time-point (Fig.3A,C; Suppl.Fig.5B). Analysis with linear  
512 mixed models revealed a significant effect of Group on MD, AD and RD in the perilesional  
513 cortex (MD:  $p \leq 0.01$ , AD:  $p \leq 0.05$ , RD:  $p \leq 0.001$ ). For all of these parameters, there was a  
514 significant interaction between Group and Time for lesion ( $p \leq 0.0001$ ) and ipsilesional  
515 hippocampus ( $p \leq 0.01$ ). Post-hoc analysis showed a significant increase in MD, AD and RD in  
516 the lesion of CCI-injured rats at 4 days ( $p \leq 0.01$ ) and 18 days post-injury ( $p \leq 0.0001$ ) vs. shams,  
517 as well as a significant effect of time in CCI-injured rats ( $p \leq 0.0001$ ). There was a significant  
518 increase in MD, AD and RD in the ipsilesional hippocampus of CCI-injured rats compared to  
519 sham-operated rats at 4 days (MD, RD:  $p \leq 0.01$ , AD:  $p \leq 0.05$ ) and 18 days post-injury (MD,  
520 AD, RD:  $p \leq 0.001$ ). All of these parameters significantly differed between 4 and 18 days in  
521 CCI-injured rats ( $p \leq 0.0001$ ). There was also a significant interaction between Group and Time  
522 effects on MD in contralesional cortex and hippocampus (both  $p \leq 0.05$ ). Post-hoc analysis  
523 showed that there was i) a weak trend towards significance for a difference in MD in  
524 contralesional cortex at 4 days between CCI-injured rats and sham-operated rats ( $p = 0.09$ ) and  
525 ii) a significant difference in MD in contralesional hippocampus between 4 and 18 days post-  
526 injury in CCI-injured rats ( $p \leq 0.0001$ ) (Suppl.Fig.5B). There was also a significant effect of  
527 Time on RD in the contralesional hippocampus (increase over time,  $p \leq 0.05$ ). Finally, there was  
528 no significant effect of Group or Time on AD or RD in the contralateral cortex and AD in  
529 contralesional hippocampus.

#### 530 **4. TSPO binding correlates with DTI parameters in the lesion of CCI-injured rats**



531 We investigated whether there was a relationship between [<sup>18</sup>F]PBR111 SUVs and DTI  
532 parameters (FA, MD, AD and RD) in the different ROIs in CCI-injured rats. A positive  
533 correlation was observed between [<sup>18</sup>F]PBR111 SUV and FA in the lesion at 4 days ( $p \leq 0.05$ ,  
534  $r = 0.48$ ) and 18 days post-injury ( $p \leq 0.05$ ,  $r = 0.52$ ), as well as negative correlations between  
535 [<sup>18</sup>F]PBR111 SUV and MD, AD and RD at 4 days (MD:  $p \leq 0.01$ ,  $r = -0.60$ ; AD:  $p \leq 0.01$ ,  $r = -$   
536  $0.59$ ; RD:  $p \leq 0.01$ ,  $r = -0.60$ ) and 18 days post-injury (MD:  $p \leq 0.01$ ,  $r = -0.62$ ; AD:  $p \leq 0.01$ ,  $r = -$   
537  $0.63$ ; RD:  $p \leq 0.01$ ,  $r = -0.62$ ) (Suppl.Fig.6). No significant correlations were observed for the  
538 other investigated brain regions.

## 539 5. Chronic deficits after CCI-injury

### 540 5.1. Disinhibition

541 **Cohort 1.** The % distance moved in the centre of the open field arena was significantly higher  
542 in CCI-injured rats than in naïve rats ( $p \leq 0.05$ ) (Fig.4A). There was no significant difference  
543 between the three groups in any of the other investigated parameters, including total distance  
544 moved and mean velocity.

545 **Cohort 2.** To corroborate this observation, we performed the same test in a separate cohort of  
546 animals at approx. 2 months post-injury (naïve:  $n = 9$ , sham:  $n = 10$ , CCI:  $n = 10$ ) and we observed  
547 a significantly increased % distance moved in the centre ( $p \leq 0.05$ ), a significantly increased  
548 number of entries into the centre ( $p \leq 0.05$ ) and a trend for an increased % time spent in centre  
549 ( $p = 0.06$ ) in CCI-injured rats compared to naïve animals (data not shown). The total distance  
550 moved (in centre + periphery) and mean velocity were not different between the three groups.

### 551 5.2. Anhedonia

552 **Cohort 1.** CCI-injured rats had a significantly lower % sucrose preference compared to sham-  
553 operated rats and all controls (sham-operated + naïve rats) ( $p \leq 0.05$ ) (Fig.4B).

### 554 5.3. Spontaneous epileptiform activity and seizures

555 **Cohort 1.** At 6 months post-injury no difference was observed between naïve, sham-operated  
556 and CCI-injured animals regarding number of epileptiform discharges (EDs) per day, number  
557 of seizures per day (all electrographic) or duration of all epileptiform activity per day (data not  
558 shown). At this time-point no behavioural seizures were observed.

559 **Cohort 1.** At 9 months post-injury behavioural seizures were observed. CCI-injured rats  
560 showed a trend for an increased frequency of behavioural seizures compared to naïve animals  
561 ( $p=0.06$ ) (Fig.5C). No difference was observed between the three groups for any other  
562 investigated parameter. Most behavioural seizures that were recorded were S1 seizures,  
563 typically displaying a spike-wave pattern (Fig.5A-1) or high-voltage rhythmic spike pattern  
564 (Fig.5A-2), and manifested by a behavioural arrest (absence-like seizures). A few other types  
565 of behavioural seizures were recorded. One CCI-injured rat experienced two S3 seizures  
566 (Fig.5A-3) and one S2 seizure during the one-week monitoring period at 9 months post-injury.  
567 Another CCI-injured rat experienced one S2 seizure. A sham-operated rat experienced one S4  
568 seizure during the one-week monitoring period. Taken together, there was only one rat with  
569 spontaneous recurrent convulsive seizures at 9 months post-injury. Hence, the incidence of  
570 posttraumatic epilepsy was 14% (1/7 vEEG monitored CCI-injured rats) in our study.

571 In addition, we investigated the evolution of spontaneous epileptiform activity and seizures  
572 over time. There were significantly more EDs and seizures per day at 9 months post-injury than  
573 at 6 months post-injury in both sham-operated and CCI-injured rats ( $p\leq 0.05$ ) (Fig.5B). Finally,  
574 the duration of all epileptiform activity per day was significantly higher at 9 months vs. 6  
575 months post-injury in these groups ( $p\leq 0.01$ ). There was no difference between sham-operated  
576 and CCI-injured rats. No naïve rats were longitudinally subjected to vEEG monitoring for the  
577 investigation of spontaneous epileptiform activity.

#### 578 5.4. Seizure susceptibility

579 **Cohort 1.** At 6 months post-injury, CCI-injured rats showed a non-significant trend for a  
580 shorter latency to the first spike compared to naïve animals ( $p=0.08$ ) (Fig.5D). A very weak  
581 trend was observed for an increased number of EDs in TBI rats compared to naïve rats ( $p=0.10$ )  
582 (Fig.5E). There was no difference between the three groups for latency to first ED and seizure,  
583 and number of spikes and seizures. At this time-point only 23% (5/22) of all rats experienced  
584 a convulsive seizure (usually S5) after injection with 25 mg/kg PTZ with no difference between  
585 the three groups ( $\chi^2$ ,  $p>0.05$ ) (data not shown).

586 **Cohort 1.** At 9 months post-injury 60% (9/15) of all rats developed a convulsive seizure  
587 (usually S5) after administration of 30 mg/kg PTZ: 25% (1/4) naïve rats, 50% (2/4) sham-  
588 operated rats and 86% (6/7) CCI-injured rats ( $\chi^2$ ,  $p\leq 0.05$ ). When comparing the three groups,  
589 we observed a trend for an increased number of convulsive seizures ( $p=0.08$ ) and a  
590 significantly increased total duration of convulsive seizures in CCI-injured rats compared to  
591 naïve animals ( $p\leq 0.05$ ) (Fig.5I). We pooled the two control groups (naïve and sham-operated  
592 animals) to be able to perform statistics regarding the latency to the first convulsive seizure  
593 and observed a significantly shorter latency to first convulsive seizure in CCI-injured rats vs.  
594 controls ( $p\leq 0.05$ ) (Fig.5H). In addition, we observed a trend for a decreased number of EDs in  
595 CCI-injured rats compared to naïve rats ( $p=0.07$ ) (Fig.5G). Upon further investigation, we  
596 observed a strong relationship between number of EDs and latency to first convulsive seizure  
597 in the rats ( $r=0.88$ ,  $p\leq 0.1$ ) (data not shown). Hence, a decreased latency to the first convulsive  
598 seizure coincides with a decreased number of EDs. We observed no difference between the  
599 three groups for any other investigated parameter (latency to first spike and ED, number of  
600 spikes and EDs) (Fig.5F).

601 One CCI-injured animal went into *status epilepticus* (six convulsive seizures in one hour) after  
602 administration of 30 mg/kg PTZ. The rat died shortly after the test, before diazepam could be  
603 administered to stop the *status epilepticus*. This was also the only CCI-injured rat that  
604 experienced multiple spontaneous convulsive seizures during the one-week monitoring period  
605 at 9 months post-injury.

606 **Cohort 2.** Additionally, we performed a PTZ test in a separate cohort of animals at approx. 6  
607 months post-injury, but without EEG monitoring. Behavioural monitoring of animals indicated  
608 that 11% (1/9) naïve rats, 40% (4/10) sham-operated rats and 78% (7/9) CCI-injured rats  
609 developed a generalised tonic-clonic (S5) seizure following administration of 30 mg/kg PTZ  
610 ( $\chi^2$ ,  $p \leq 0.01$ ).

## 611 **5.5. Impaired visuospatial learning**

612 **Cohort 1.** Analysis with linear mixed models showed a significant effect of both Group  
613 ( $p \leq 0.05$ ) and Time (= trial block) ( $p \leq 0.0001$ ) on both escape latency and path length to the  
614 platform. There was no significant interaction between Group and Time. Post-hoc analysis  
615 revealed that CCI-injured animals had a significantly longer escape latency than naïve animals  
616 ( $p \leq 0.05$ ) and a weak trend for a longer latency compared to sham-operated rats ( $p = 0.09$ )  
617 (Fig.4C). The difference was seen to be greatest at the second day of training. CCI-injured  
618 animals also showed a trend for an increased path length compared to naïve rats ( $p = 0.06$ ) (data  
619 not shown). There was no difference in the swimming speed between the three groups.

620 Though a numerically lower % time spent in the target quadrant during the probe trial was  
621 observed in CCI-injured animals versus the controls, no significant difference between the  
622 three groups was noted. There was a trend for a lower frequency of platform crossings in CCI-  
623 injured rats compared to sham-operated rats ( $p = 0.08$ ) (data not shown).

## 624 **6. Correlation between subacute TSPO binding, microstructural changes, lesion** 625 **volume and chronic deficits in CCI-injured rats**

626 First of all, we investigated if there was a correlation between i) subacute TSPO expression  
627 ( $[^{18}\text{F}]\text{PBR111}$  SUV) in perilesional cortex, ipsilesional hippocampus, **contralesional cortex and**  
628 **contralesional hippocampus** of CCI-injured rats, ii) DTI metrics in these brain regions **and iii)**  
629 **lesion volume** on the one hand and chronic behavioural deficits on the other hand (i.e.,  
630 parameters that were significantly different in CCI-injured rats compared to controls or showed  
631 a trend towards significance). In addition, we investigated whether the evolution in TSPO  
632 expression, DTI metrics **and lesion volume** (i.e., the % change in SUV, FA, MD, AD, RD **and**  
633 **lesion volume** over time) correlated with the chronic functional outcome.

634 Several correlations were observed between individual TSPO PET and DTI parameters on the  
635 one hand and chronic deficits on the other hand (**ipsilesional brain regions: Fig.6 and Fig.7,**  
636 **contralesional brain regions: Suppl.Fig.7 and Suppl.Fig.8**). Correlations that were significant  
637 are summarised in Table 1 (TSPO PET **in ipsilesional brain regions**), Table 2 (DTI **in**  
638 **ipsilesional brain regions**), **Supplementary Table 1 (TSPO PET in contralesional brain regions)**  
639 **and Supplementary Table 2 (DTI in contralesional brain regions)**. Most importantly, both  
640 TSPO PET and DTI parameters correlated with disinhibition in the open field, spontaneous  
641 behavioural seizure frequency at 9 months post-injury, increased seizure susceptibility, and  
642 MWM performance.

643 **The lesion volume at 4 and 18 days post-injury correlated with the number of EDs during the**  
644 **PTZ test at 6 months post-injury (respectively  $r = 0.67$ ,  $p \leq 0.05$  and  $r = 0.68$ ,  $p \leq 0.05$ )**  
645 **(Suppl.Fig.9A,B)**. There were no significant correlations with any other chronic deficit.

## 646 **7. ROC curve analysis**

647 ROC curves were plotted for those *in vivo* imaging parameters that correlated significantly with  
648 chronic deficits in the Pearson correlation analysis (see Tables 1, 2, Supplementary Tables 1,  
649 2). ROC curves were only plotted if there was a sufficient number of animals ( $n \geq 5$ ) in each  
650 group (i.e., CCI-injured animals with deficit and CCI-injured animals without deficit). This  
651 excluded ROC curves with behavioural seizure frequency at 9 months and seizure  
652 susceptibility at 6 and 9 months post-injury as outcome. In total, 11 ROC curves were plotted:  
653 six for ipsilesional measurements (Fig.8) and five for contralesional measurements  
654 (Suppl.Fig.10).

655 While the [ $^{18}\text{F}$ ]PBR111 SUV in perilesional cortex at 21 days post-injury showed relatively  
656 good sensitivity and specificity in distinguishing between CCI-injured rats with and without  
657 disinhibition in the open field (area under the ROC curve  $\text{AUC} = 0.80$ ,  $p=0.06$ ), the relative  
658 change over time in [ $^{18}\text{F}$ ]PBR111 SUV in this brain region had a much higher sensitivity and  
659 specificity in distinguishing between CCI-injured rats with and without disinhibition ( $\text{AUC} =$   
660  $1.00$ ,  $p \leq 0.01$ ) (Fig.8A,B). The relative change over time in FA in ipsilesional hippocampus  
661 showed no good sensitivity and specificity in distinguishing between CCI-injured rats with and  
662 without disinhibition ( $\text{AUC} = 0.57$ ,  $p > 0.05$ ) (Fig.8D). The [ $^{18}\text{F}$ ]PBR111 SUV in contralesional  
663 cortex at 21 days post-injury was also not able to distinguish between CCI-injured rats with  
664 and without disinhibition ( $\text{AUC} = 0.75$ ,  $p > 0.05$ ). However, the [ $^{18}\text{F}$ ]PBR111 SUV in  
665 contralesional hippocampus at this time-point was able to distinguish between the CCI-injured  
666 rats with and without disinhibition ( $\text{AUC} = 0.85$ ,  $p \leq 0.05$ ) (Suppl.Fig.10A,B). The FA in  
667 contralesional cortex at 18 days post-injury showed also very high sensitivity and specificity  
668 in distinguishing between rats with and without disinhibition ( $\text{AUC} = 0.92$ ,  $p \leq 0.01$ ), but the  
669 other investigated parameters (relative change over time in FA in contralesional cortex:  $\text{AUC}$   
670  $= 0.62$ ,  $p > 0.05$ ; MD in contralesional hippocampus at 18 days post-injury:  $\text{AUC} = 0.60$ ,  
671  $p > 0.05$ ) did not (Suppl.Fig.10C,D,E).

672 The relative change over time in [<sup>18</sup>F]PBR111 SUV in perilesional cortex showed relatively  
673 good sensitivity and specificity in distinguishing between CCI-injured rats with and without a  
674 learning deficit in the MWM test (AUC = 0.79, p=0.06) (Fig.8C). MD and RD in ipsilesional  
675 hippocampus at 18 days post-injury showed very good sensitivity and specificity in  
676 distinguishing between CCI-injured rats with and without a learning deficit (respectively AUC  
677 = 1.00, p≤0.01 and AUC = 0.96, p≤0.01) (Fig.8E,F).

## 678 **8. Stepwise regression analysis**

679 Finally, we performed stepwise regression analysis to investigate whether ipsilesional and  
680 contralesional TSPO PET data, DTI metrics or lesion volume alone are sufficient to predict the  
681 long-term functional deficits or whether combining TSPO PET, DTI and lesion volume has an  
682 added value. To this end, automated forward stepwise regression analysis was done with five  
683 different sets of possible predictors, i.e., only TSPO PET parameters, only DTI metrics, only  
684 lesion volumes, TSPO PET and DTI measurements combined and TSPO PET, DTI and lesion  
685 volume assessments combined to build different regression models. The models were then  
686 compared to see which of the five models was best at explaining the variability in the data (i.e.,  
687 the chronic functional deficits). The obtained data are summarised in Table 3 (TSPO PET, DTI  
688 and TSPO PET + DTI models) and Supplementary Table 3 (lesion volume models and  
689 comparison between TSPO PET + DTI and TSPO PET + DTI + lesion volume models).

690 Both TSPO PET and DTI parameters alone could explain some of the variability in the %  
691 distance moved in the centre of the open field of CCI-injured rats (respectively  $R^2$  adj. = 0.63,  
692 p=0.001 and  $R^2$  adj. = 0.54, p=0.0043), but combining these parameters resulted in a better  
693 model ( $R^2$  adj. = 1.00, p<0.0001).

694 Variability in the sucrose preference in CCI-injured rats could be explained by variability in  
695 the DTI parameters ( $R^2$  adj. = 0.89,  $p < 0.0001$ ), but could be explained even better by a  
696 combination of DTI and TSPO PET parameters ( $R^2$  adj. = 1.00,  $p < 0.0001$ ).

697 Both TSPO PET and DTI parameters alone can predict the variability in behavioural SRS  
698 frequency at 9 months post-injury (respectively  $R^2$  adj. = 0.89,  $p = 0.0214$  and  $R^2$  adj. = 0.83,  
699  $p = 0.0395$ ), but a combination of TSPO PET and DTI parameters is even better at predicting  
700 the variability in this behavioural outcome parameter ( $R^2$  adj. = 1.00,  $p = 0.0008$ ).

701 DTI parameters are good at predicting the variability in the increased seizure susceptibility at  
702 6 months post-injury (latency to first spike:  $R^2$  adj. = 1.00,  $p = 0.0002$ ; number of EDs:  $R^2$  adj.  
703 = 1.00,  $p = 0.0003$ ).

704 Both TSPO PET and DTI parameters alone as well as the combination of these parameters can  
705 predict the variability in the increased seizure susceptibility at 9 months post-injury: latency to  
706 first convulsive seizure (TSPO PET:  $R^2$  adj. = 0.91,  $p = 0.0122$ ; DTI:  $R^2$  adj. = 1.00,  $p = 0.0017$ ;  
707 TSPO PET + DTI:  $R^2$  adj. = 1.00,  $p = 0.0012$ ), number of convulsive seizures (TSPO PET:  $R^2$   
708 adj. = 0.98,  $p = 0.0013$ ; DTI:  $R^2$  adj. = 1.00,  $p = 0.0012$ ; TSPO PET + DTI:  $R^2$  adj. = 1.00,  
709  $p = 0.0015$ ) and total duration of convulsive seizures (TSPO PET:  $R^2$  adj. = 1.00,  $p = 0.0181$ ;  
710 DTI:  $R^2$  adj. = 1.00,  $p = 0.0009$ ; TSPO PET + DTI:  $R^2$  adj. = 1.00,  $p = 0.0009$ ).

711 Variability in MWM performance can mainly be explained by DTI metrics (escape latency  
712 MWM training day 2:  $R^2$  adj. = 1.00,  $p = 0.0085$ ; % improvement escape latency MWM training  
713 day 1 vs. day 2:  $R^2$  adj. = 0.95,  $p = 0.0002$ ).

714 Variability in lesion volume can explain some of the variability in the % distance moved in the  
715 centre of the open field of CCI-injured rats ( $R^2$  adj. = 0.36,  $p = 0.0285$ ) as well as in the number  
716 of EDs during the seizure susceptibility test at 6 months ( $R^2$  adj. = 0.40,  $p = 0.0221$ ), though not



717 as good as TSPO PET and DTI parameters can. Variability in lesion volume could not explain  
718 the variability in any other functional outcome parameter. Adding lesion volume assessments  
719 to the TSPO PET + DTI models did not improve any of these prognostic models.

720

721

## 722 Discussion

723 The main finding of our study was that both subacute TSPO expression and changes in DTI  
724 metrics following CCI-injury correlated with several chronic sequelae. Not only robust changes  
725 in TSPO expression and DTI metrics in the ipsilesional brain regions correlated with multiple  
726 long-term functional deficits, but also the variability in these parameters in the contralesional  
727 brain regions correlated well with these deficits. Importantly, not only the absolute SUV and  
728 DTI values at distinct time-points were good correlates of the functional outcome, but also the  
729 relative change in TSPO expression and DTI metrics over time. Some of the TSPO PET and  
730 DTI measurements showed good sensitivity and specificity in distinguishing TBI rats with and  
731 without a particular chronic deficit, making them promising prognostic biomarkers. Depending  
732 on the behavioural deficit that is investigated, TSPO PET data or DTI metrics alone, or the  
733 combination of the two imaging modalities, can predict the long-term deficit. DTI metrics  
734 could predict all the investigated chronic deficits, but TSPO PET could also predict many  
735 chronic sequelae, including disinhibition in the open field, spontaneous behavioural seizure  
736 frequency and seizure susceptibility at 9 months post-injury. In several instances, combining  
737 TSPO PET and DTI parameters resulted in the best prognostic models for the chronic outcome  
738 (open field behaviour, sucrose preference and spontaneous behavioural seizure frequency).

### 739 1. Subacute brain inflammation and microstructural changes after TBI

740 High TSPO binding of [<sup>18</sup>F]PBR111 was observed at 7 days post-contusion, which decreased  
741 over time. This temporal profile was similar to previously reported binding of other TSPO  
742 radioligands in rat contusion models.<sup>16, 17, 19</sup>

743 In addition, we performed immunohistochemical stainings against CD11b (expressed by  
744 microglia/macrophages) and GFAP (expressed by astrocytes) as well as *in vitro*  
745 autoradiography with the TSPO radioligand [<sup>3</sup>H]PK11195 at 7 days post-injury, when

746 [<sup>18</sup>F]PBR111 SUVs in CCI-injured animals were the highest. At this time-point we observed  
747 high densities of microglia/macrophages and astrocytes in the perilesional cortex and  
748 ipsilesional hippocampus of CCI-injured rats. There was no difference between sham-operated  
749 rats and naïve animals, indicating that there is no detectable inflammatory response following  
750 craniectomy, at least not at this time-point (Suppl.Fig.2 and 3). A qualitative comparison of  
751 TSPO *in vitro* autoradiographs, CD11b- and GFAP-stained sections of the same animals  
752 suggests that at this time-point primarily microglia/macrophages contribute to the TSPO signal  
753 (Suppl.Fig.4). However, a contribution of astrocytes to the TSPO signal is likely. Several  
754 studies in TBI models using double stainings came to the same conclusion and pointed to  
755 microglia/macrophages as the main cellular sources of the TSPO signal with an additional  
756 contribution of astrocytes.<sup>16, 17</sup>

757 PET imaging with second-generation TSPO radiotracers to assess brain inflammation has been  
758 applied in clinical studies of several neurological and neuropsychiatric disorders, including  
759 traumatic brain injury, brain infarct, brain tumour, multiple sclerosis, Alzheimer's disease and  
760 schizophrenia. While promising results have been obtained, several limitations of these  
761 radiotracers have been observed. A human gene polymorphism in *TSPO* (rs6971, resulting in  
762 Ala147Thr substitution in TSPO) determines the binding affinity of the PET tracers, resulting  
763 in a trimodal distribution in binding affinity amongst subjects.<sup>43, 44</sup> There are low-affinity  
764 binders, high-affinity binders and mixed affinity binders. Knowledge of the individual binding  
765 status of the patient is therefore required to correctly interpret TSPO PET data. Third-  
766 generation TSPO tracers that are less sensitive to this differential binding status are being  
767 evaluated. Quantification of TSPO PET results also remains an issue.<sup>45</sup> Many studies using  
768 arterial blood sampling for kinetic modelling have reported considerable variability in blood  
769 measurements. Moreover, there is no true reference region that can be used for reference tissue  
770 modelling.

771 Decreased anisotropy and increased diffusivity have previously been observed after  
772 experimental TBI (reviewed in <sup>47</sup>) in line with our findings at 4 days post-TBI. Neuronal cell  
773 loss, resulting in a decreased neurite density, axon damage, demyelination and disorganised  
774 gliosis can underlie the decreased anisotropy. The subsequent increase in anisotropy at 18 days  
775 post-TBI may be due to neuronal regeneration/reorganisation (e.g., axon sprouting),  
776 remyelination and organised gliosis (e.g., glial scarring). Johnstone and colleagues suggested  
777 that the increased FA that they observed following FPI in rats was related to structural  
778 reorganisation, since it coincided with recovery of neuronal responsiveness.<sup>48</sup> Budde and  
779 colleagues, however, attributed increased FA following CCI-injury in rats to coherent  
780 organisation of reactive astrocytes (i.e., glial scarring) and not to regeneration/structural  
781 reorganisation of axons.<sup>49</sup> We cannot conclude which process attributed to the increased FA in  
782 our study. Although the increase in FA in perilesional cortex over time did not coincide with  
783 an increase in TSPO expression, it cannot be excluded that glial scarring did not contribute to  
784 the increased FA. The decrease in TSPO over time may primarily reflect a decrease in  
785 microglial density/activity, rather than a decrease in reactive astrocytes, which are the main  
786 contributors to the glial scar. The increased diffusivity may be explained by vasogenic edema,  
787 neuronal cell death and gliosis (e.g., amoeboid microglia).<sup>47</sup> A worsening of the diffusivity  
788 over time may reflect secondary injury.<sup>50</sup> Furthermore, we observed a correlation between high  
789 TSPO binding in the lesion on the one hand and high anisotropy (FA) and low diffusivity (MD,  
790 AD and RD) in the lesion on the other hand, supporting the hypothesis that gliosis contributed  
791 to the observed changes in DTI parameters. A high infiltration of TSPO-positive immune cells  
792 (i.e. high cellularity) into the lesioned area that is otherwise only filled with cell debris and  
793 extracellular fluid can explain lower diffusivity and higher anisotropy.

794 TBI results in tissue loss, which is most prominent and acute at the lesion site. Also in  
795 perilesional areas there is damage and ultimately loss of neurons, which is part of the

796 secondary, delayed injury. Damage to neurons elicits a complex neuroinflammatory response,  
797 involving many immune-competent cells. Part of their job is to remove the cellular debris,  
798 which is caused by the loss of neurons. Hence, one imaging signature of tissue loss is an  
799 increase in immune cells that clear the debris, which may be detected by TSPO PET. Tissue  
800 loss can also cause hypometabolism, which can be measured with fluorodeoxyglucose (FDG)  
801 PET. Increased inflammation and hypometabolism have been shown to occur in parallel after  
802 TBI.<sup>17</sup> Complete loss of neurons, damage to cell membranes and axonal injury can cause an  
803 increased mean diffusivity and decreased anisotropy, as we have observed acutely in our study.  
804 Removal of cell debris by immune cells can increase the diffusivity even further. Delayed loss  
805 of neurons in perilesional areas (secondary injury) can also cause a further increase in  
806 diffusivity. Indeed, we have observed a worsening of the diffusivity over time in our study.  
807 Hence, tissue loss also has several imaging signatures that can be measured with DTI.

## 808 **2. Chronic sequelae of TBI**

809 CCI-injured rats exhibited several chronic deficits compared to naïve and/or sham-operated  
810 animals. While naïve and sham-operated rats did not differ significantly from each other, we  
811 observed that in several instances CCI-injured animals only differed significantly from naïve  
812 animals and not from sham-operated rats. Sham-operated rats often showed an intermediate  
813 response compared to naïve and CCI-injured rats. In the open field, sham rats showed very  
814 similar behaviour as the CCI-injured rats. This supports the hypothesis that sham-operated rats  
815 are not completely normal and underlines the importance of including naïve animals as a  
816 secondary control group. It has previously been shown that craniotomised animals can display  
817 behavioural deficits compared to naïve animals.<sup>30</sup>

818 CCI-injured rats exhibited an increased tendency to enter the centre of the open field compared  
819 to controls, which may be due to disinhibition and impulsivity (common symptoms in TBI

820 patients<sup>51</sup> and observed in rats following CCI-injury<sup>52</sup>) or decreased anxiety, which has been  
821 observed in CCI-injured mice.<sup>53</sup> While the % distance moved in the centre of the open field  
822 was increased, the total distance moved and the mean velocity were not altered, indicating that  
823 there was no general hyperactivity in the CCI-injured animals. Several studies have observed  
824 increased thigmotaxis in an open field following experimental TBI in rodents, while some  
825 failed to observe a difference between TBI and sham-operated animals. Differences in  
826 observation might be explained by differences in injury type, location and severity, species and  
827 strain differences, and a different timing of the open field test.<sup>53-57</sup> Reduced anxiety-like  
828 behaviour and increased disinhibition/impulsivity has been observed in other behavioural tests  
829 following CCI-injury, including elevated zero maze and light-dark box tests and the delay  
830 discounting task.<sup>52, 53</sup>

831 CCI-injured rats exhibited anhedonia in the chronic period, which is an indication of  
832 depression-like behaviour. Some studies have failed to observe anhedonia following  
833 experimental TBI in rodents, which could be due to differences in injury type, location and  
834 severity, species and strain differences, and a different timing of the sucrose preference test.<sup>53,</sup>

835 <sup>54</sup>

836 Most of the EDs and seizures that we observed during this study were either spike-wave  
837 discharges (SWDs) or high-voltage rhythmic spike (HVRS) discharges and were bilateral in  
838 onset. If there was a behavioural manifestation, then it was usually a behavioural arrest. These  
839 SWDs and HVRS discharges have been shown to occur spontaneously in this and other rat  
840 strains (both inbred and outbred) and their occurrence progresses with age, which complicates  
841 the use of rodents to study acquired epilepsy.<sup>58-60</sup> Indeed, we also observed an increased  
842 frequency in EDs and seizures over time (from 6 to 9 months post-injury) in both sham-  
843 operated and CCI-injured rats, which suggest an aging effect that might have been slightly  
844 exacerbated by the CCI-injury (given the numerically higher frequency of EDs and seizures in

845 this group). Unfortunately, we cannot confirm this aging effect in naïve rats, since none of the  
846 naïve rats were vEEG-monitored at both time-points for the occurrence of spontaneous  
847 epileptiform activity. While some have argued that there is no difference in the occurrence of  
848 SWDs between sham-operated and fluid percussion-injured (FPI) animals<sup>61</sup>, others have  
849 described a higher frequency of SWDs in FPI animals compared to shams.<sup>62</sup> In our study we  
850 did not observe a significant difference between naïve, sham-operated and CCI-injured rats  
851 regarding the occurrence of EDs. There was, however, an increased frequency of behavioural  
852 seizures in CCI-injured rats compared to naïve rats at the final time-point. Because of the  
853 controversy regarding SWDs, HVRS discharges and non-convulsive (especially absence-like)  
854 seizures in models of posttraumatic epilepsy, we limit ourselves to the occurrence of convulsive  
855 (i.e., S3-5) seizures to make conclusions regarding the development of posttraumatic epilepsy  
856 (PTE) in our CCI rat model. At 6 months post-injury none of the rats had any convulsive  
857 seizures. At the 9-month time-point, one CCI-injured animal experienced two spontaneous  
858 convulsive seizures during the one-week monitoring period. This rat was considered epileptic  
859 and was also the only animal that went into *status epilepticus* during the subsequent PTZ test.  
860 It is important to note that this rat also had the highest frequency of spontaneous non-convulsive  
861 behavioural seizures during the one-week monitoring period at 9 months post-injury. Hence,  
862 14% (1/7 vEEG-monitored) rats developed posttraumatic epilepsy by the end of our study,  
863 which is comparable to the study of Kelly and colleagues, who perceived spontaneous  
864 convulsive seizures in 15% of all CCI-injured rats (5% (2/40) in vEEG-monitored and 19%  
865 (17/88) in video-monitored rats).<sup>63</sup> The development of posttraumatic epilepsy has also been  
866 studied after CCI-injury in mice. Bolkvadze and Pitkänen observed spontaneous convulsive  
867 seizures in 9% of the CCI-injured mice<sup>64</sup>, while Hunt and colleagues reported that 13-18% of  
868 severely injured CCI mice had spontaneous convulsive seizures.<sup>65, 66</sup> In our study one sham-  
869 operated rat experienced one convulsive seizure during the monitoring period, which is

870 uncommon, but has been reported previously by others as well.<sup>67</sup> None of the naïve animals  
871 had convulsive seizures.

872 We observed a clear increase in seizure susceptibility during the second PTZ assay at 9 months  
873 post-injury when we used 30 mg/kg PTZ (86% CCI rats developed convulsive seizures vs. 38%  
874 controls), but not at 6 months post-injury with the 25 mg/kg PTZ dose. However, in a separate  
875 cohort (cohort 2), we also observed a clear increase in seizure susceptibility at 6 months post-  
876 injury when using the 30 mg/kg dose (78% CCI rats vs. 26% controls) (similar to previous  
877 observations in CCI mice at this time-point<sup>64</sup>), suggesting that the dose of PTZ is important to  
878 distinguish between TBI animals and controls. Similar observations have been made by the  
879 group of Pitkänen, who also employed 25 mg/kg and 30 mg/kg PTZ doses in Sprague-Dawley  
880 rats to assess seizure susceptibility after TBI (FPI).<sup>24, 40</sup>

881 An interesting observation in our study was the inverse relationship between the number of  
882 EDs and the latency to first convulsive seizure following PTZ administration. It seems that  
883 typically PTZ initially induces an increased frequency of EDs until a certain threshold is  
884 reached, which results in a convulsive seizure (usually a tonic-clonic S5 seizure). In animals  
885 that quickly got a convulsive seizure there was a low number of EDs, while in animals that got  
886 a convulsive seizure after a long time there was a high number of EDs. At 6 months, 25 mg/kg  
887 PTZ caused an increased number of EDs in CCI-injured rats, but hardly any convulsive  
888 seizures. At 9 months, 30 mg/kg PTZ caused convulsive seizures in many CCI-injured rats,  
889 which occurred relatively quickly after PTZ administration. At the same time, there were less  
890 EDs in this group during this test. A very strong relationship between the number of EDs and  
891 the latency to first convulsive seizure was observed at the subject level.

892 The CCI rats exhibited a clear deficit in the acquisition of the MWM task, which was most  
893 pronounced on day 2 of the training phase. While the CCI-injured rats had a slower learning



894 curve, they did not show a difference in escape latency and path length at the end of the  
895 acquisition phase compared to sham and naïve rats. So while CCI-injured rats were initially  
896 slower in learning the location of the platform, they managed to learn it equally well as the  
897 sham-operated and naïve rats by the end of the 8 days of the training period. In addition, they  
898 also displayed a slight non-significant deficit in the retention trial. Deficits in hippocampus-  
899 dependent spatial learning and memory have consistently been shown after experimental TBI  
900 in rodents using the MWM test.<sup>68-70</sup> Cognitive impairment following experimental TBI has  
901 been shown using several different paradigms, showing both retrograde and anterograde  
902 amnesia, as well as working memory deficits (reviewed in <sup>71</sup>).

### 903 **3. Correlation between subacute brain inflammation, microstructural alterations,** 904 **lesion volume and chronic TBI sequelae**

905 Several correlations were observed between subacute TSPO expression and DTI metrics in  
906 ipsi- and contralesional brain regions (cortex and hippocampus) and long-term functional  
907 deficits. Importantly, not only the absolute [<sup>18</sup>F]PBR111 SUVs and DTI values at the two  
908 subacute time-points correlated with chronic outcome, but also the relative change in TSPO  
909 expression and DTI parameters over time, i.e., the dynamics of the neuroinflammatory  
910 response and degeneration/regeneration processes.

911 Surprisingly, a pronounced decrease in TSPO expression in the perilesional cortex over time  
912 correlated with a higher disinhibition level in CCI rats as suggested by the open field test.  
913 Interestingly, TSPO itself is involved in the synthesis of neurosteroids, some of which have  
914 anxiolytic effects (e.g., allopregnanolone). Overexpression of TSPO in mice has been shown  
915 to produce anxiolytic behaviour.<sup>72</sup> While no positive correlation could be established between  
916 the subacute increase in TSPO and the long-term increase in disinhibition, it cannot be  
917 excluded that TSPO played some role in the subsequent disinhibited behaviour. CCI animals

918 with an increase in FA in ipsilesional hippocampus over time showed less disinhibition than  
919 animals where the initial FA deficit did not resolve or even worsened over time. An increase  
920 in FA might indicate neuronal regeneration and repair, which may explain the better functional  
921 outcome.<sup>47, 73</sup> Johnstone and colleagues observed increased fractional anisotropy in the chronic  
922 period following FPI and speculated that this may be related to structural reorganisation, which  
923 may have explained the recovery of neuronal responsiveness that they observed.<sup>48</sup> Similarly,  
924 in our study, the increased FA may reflect structural reorganisation that is responsible for the  
925 better functional outcome on this test.

926 High levels of subacute TSPO in the ipsilesional hippocampus and perilesional cortex  
927 correlated with high spontaneous behavioural seizure frequency and increased seizure  
928 susceptibility at 6 and 9 months post-TBI. Animals that had a minimal decrease in TSPO  
929 binding over time, i.e., persistent inflammation, were shown to have a high frequency of  
930 behavioural seizures and increased seizure susceptibility at 9 months post-TBI. Interestingly,  
931 the only rat that developed spontaneous recurrent convulsive seizures in this study and that  
932 went into *status epilepticus* following PTZ administration at the final time-point was also the  
933 only animal that had a prominent increase in subacute TSPO expression over time in the  
934 perilesional cortex. Several inflammatory mediators have been implicated in epileptogenesis,  
935 seizure initiation and TBI-induced pathogenesis and might play a role in the development of  
936 posttraumatic epilepsy (PTE) (reviewed in <sup>7</sup>). A pronounced and enduring inflammatory  
937 response following TBI might lead to the development of PTE, as supported by our study.  
938 Changes in FA, MD, AD and RD also correlated with increased seizure susceptibility. A more  
939 pronounced deficit in FA, MD, AD and RD in perilesional cortex correlated with a shorter  
940 latency to the first spike during the 6-month PTZ assay. Our observations are in line with  
941 studies performed by Kharatishvili and Immonen and colleagues, who showed that increased  
942 average diffusion in ipsilesional hippocampus and perilesional cortex correlated with increased

943 chronic seizure susceptibility after FPI (latency to first spike, number of spikes and number of  
944 EDs) and with the severity of mossy fiber sprouting post-FPI, a form of hippocampal circuitry  
945 reorganisation that is thought to be related to epileptogenesis.<sup>24, 25</sup> This indicates that these  
946 diffusion measurements can be good predictors of seizure susceptibility in different TBI  
947 models. CCI rats with a limited increase or even a decrease in FA over time in ipsilesional  
948 hippocampus had a higher number of EDs during the PTZ assay at 6 months post-injury, while  
949 a more pronounced increase in FA in perilesional cortex over time correlated with a shorter  
950 latency to the first convulsive seizure during the 9-month PTZ assay. An increase in FA can be  
951 due to increased plasticity/structural reorganisation (beneficial or aberrant) or increased  
952 organised gliosis (e.g., glial scarring).<sup>48, 49</sup>

953 A pronounced subacute neuroinflammatory response in the perilesional cortex correlated with  
954 a more severe learning deficit in our CCI rats. Part of the lesioned and perilesional cortex is  
955 the parietal association cortex, which is implicated in spatial processing. Lesions of this area  
956 have been shown to cause deficits in the acquisition of the MWM task.<sup>74</sup> Neuroinflammation  
957 has been shown to affect cognition; inhibition of subacute inflammation has been demonstrated  
958 to improve the cognitive outcome following experimental TBI.<sup>9-11</sup> CCI rats with a more  
959 pronounced increase in MD and RD in ipsilesional hippocampus at 18 days post-injury  
960 displayed a greater deficit in the acquisition of the MWM task. Similarly, Immonen et al.  
961 showed that FPI rats with a higher increase in average diffusion in ipsilesional hippocampus at  
962 23 days post-injury exhibited a greater impairment in the MWM test at 7 months post-injury.<sup>26</sup>  
963 This research group also observed a correlation between average diffusion in hippocampus at  
964 several acute and chronic time-points post-FPI and mossy fiber sprouting at a chronic time-  
965 point.<sup>24</sup> Interestingly, inhibition of mossy fiber sprouting has been shown to coincide with an  
966 amelioration of MWM performance in pilocarpine-treated mice.<sup>75</sup>

967 The interpretation of diffusion metrics remains challenging, since various cellular alterations  
968 can cause a similar DTI abnormality. In addition, several cellular processes (increased  
969 plasticity, gliosis) can have both beneficial and detrimental effects, possibly affecting different  
970 behavioural processes in a different manner.

971 Interestingly, not only the pronounced changes in TSPO expression and microstructure in the  
972 ipsilesional brain regions correlated with the chronic outcome, but also the variability in these  
973 parameters in the contralesional brain regions correlated well with the long-term deficits.

974 Surprisingly, the lesion volume only correlated with seizure susceptibility at 6 months post-  
975 injury and not with any other chronic deficit. A bigger lesion in the subacute phase correlated  
976 with an increased seizure susceptibility at this time-point. Bigger lesion volumes have been  
977 shown to be associated with a worse outcome after TBI.<sup>28</sup>

#### 978 **4. Prognostic biomarkers and models**

979 ROC curve analysis showed that certain specific TSPO PET and DTI parameters had good  
980 sensitivity and specificity (area under the ROC curve = 0.85-1.00) to distinguish between  
981 traumatised rats with and without a particular chronic deficit and hence are very promising  
982 prognostic biomarkers for the long-term outcome following TBI.

983 Stepwise regression analysis showed that both TSPO PET and DTI data alone, as well as the  
984 combination of TSPO PET and DTI parameters provided good regression models (adjusted R<sup>2</sup>  
985 = 0.54-1.00) to explain the variability in the chronic outcome parameters, depending on which  
986 behavioural parameter was investigated. DTI parameters could predict all investigated chronic  
987 deficits. TSPO PET parameters could also predict several of the investigated TBI sequelae. In  
988 several cases, combining TSPO PET and DTI parameters resulted in the best prognostic  
989 models. Adding lesion size as a predictor to these models did not improve them. The TSPO

990 PET and DTI measurements seem to provide more information about the underlying biological  
991 processes that ultimately lead to the development of these chronic deficits and are better  
992 predictors of the long-term outcome than the lesion volume. These data indicate that both  
993 TSPO PET and DTI parameters could be useful characteristics to be implemented into novel,  
994 improved prognostic models for the outcome of TBI. Moreover, these models may give a more  
995 precise prognosis than the current prognostic models. More research is warranted to conclude  
996 whether such prognostic models would be of value to predict the outcome of individual  
997 subjects.

998 An interesting study by Shultz and colleagues investigated the potential of several  
999 neuroimaging ( $^{18}\text{F}$ FDG PET and T<sub>2</sub>-weighted MRI) and behavioural assessments as possible  
1000 predictors of posttraumatic epilepsy in an FPI rat model. Of all the investigated parameters,  
1001 only measurements of glucose metabolism (using FDG PET) in the ipsilesional hippocampus  
1002 at different time-points after TBI were able to predict the epileptic outcome in this model. In  
1003 addition, they observed hippocampal deformation (assessed by large-deformation high-  
1004 dimensional mapping of hippocampal morphometry) in the subacute phase that was different  
1005 between epileptic and non-epileptic TBI rats. All investigated MRI parameters (including  
1006 volumetric and MRI intensity analyses of several brain regions) failed to predict epilepsy  
1007 outcome.<sup>76</sup> Based on these and our observations, it would be useful to investigate and compare  
1008 i) brain inflammation (using TSPO PET), ii) microstructural changes (using DTI), and iii)  
1009 hypometabolism (using FDG PET) as potential predictors of posttraumatic epilepsy and other  
1010 chronic TBI outcomes in a single study to be able to draw conclusions regarding their  
1011 respective prognostic potential and potentially added value. Interestingly, Yu and colleagues  
1012 have compared TSPO PET imaging with FDG PET imaging in a FPI rat model and concluded  
1013 that TSPO PET was much more sensitive for the detection of posttraumatic pathologies than

1014 FDG PET.<sup>17</sup> However, whether TSPO imaging has a better prognostic value for chronic TBI  
1015 outcome than FDG imaging needs yet to be confirmed.

## 1016 **5. Limitations of our study**

1017 A limitation of our study was the fact that MRI and PET scans were not performed on the same  
1018 days in the animals (e.g., both on day 7 and day 21 post-injury), which would have allowed a  
1019 better comparison between DTI and TSPO PET data. Unfortunately, this was not possible in  
1020 our study for logistic reasons. Moreover, it is not good for animals to be anaesthetised for a  
1021 long time or on consecutive days. The animals need to recover in between consecutive  
1022 “anaesthesia sessions” (i.e., surgery (trauma induction), MRI and PET scanning sessions),  
1023 especially shortly after traumatic brain injury. For this reason, we chose to perform the first  
1024 MRI scanning session on day 4 after trauma induction and the first PET scanning session on  
1025 day 7 (based on the peak of TSPO expression that was previously reported in literature).  
1026 Advances in combined preclinical PET/MR imaging will eventually help to solve these issues  
1027 and allow to perform PET and MRI together in one (overall shorter) scanning session.

1028 A second limitation of our study are the rather short vEEG monitoring periods. Monitoring the  
1029 animals for a longer time would have increased the chance of detecting additional spontaneous  
1030 convulsive seizures. However, since the incidence of posttraumatic epilepsy in our study is  
1031 similar to the one reported by Kelly et al., we believe that the observed incidence is not an  
1032 underestimation.

1033

1034 **Conclusion**

1035 Our study shows that subacute neuroinflammation, measured by PET imaging with a TSPO  
1036 radioligand, and microstructural changes, measured by DTI, correlate with several chronic  
1037 deficits after CCI-injury in rats, including disinhibition, spontaneous behavioural seizure  
1038 frequency, seizure susceptibility and impaired visuospatial learning. Not just the robust  
1039 alterations in brain inflammation and microstructure in the ipsilesional hemisphere correlated  
1040 well with chronic TBI sequelae, but also the variability in TSPO expression and DTI metrics  
1041 in the contralesional hemisphere. Importantly, not only the absolute PET/DTI values at the two  
1042 subacute time-points correlated with chronic outcome, but also the subacute evolution of brain  
1043 inflammation and microstructural changes proved to be good correlates of long-term functional  
1044 deficits. Combining TSPO PET and DTI seemed to have an added value in the prediction of  
1045 some chronic deficits. Overall, our study suggests that TSPO PET/DTI parameters could be  
1046 useful prognostic biomarkers and be implemented in novel, improved prognostic models for  
1047 prediction of the development of different TBI sequelae.

1048

1049 **Acknowledgments**

1050 We thank Krystyna Szewczyk, Annemie Van Eetveldt, Philippe Joye and Caroline Berghmans  
1051 for their excellent technical assistance. This research was supported by ERA-NET  
1052 NEURON/Research Foundation Flanders GA00913N. Stephan Missault has a PhD fellowship  
1053 of the Research Foundation Flanders (11K3714N/11K3716N). The 7T PharmaScan MR  
1054 system was purchased through Hercules foundation funding (Belgium) under the promotership  
1055 of Prof. Annemie Van der Linden. We also acknowledge the Interuniversity Poles of Attraction  
1056 of the Belgian Federal Science Policy Office (IAP7/16), Belgian Alzheimer Research  
1057 Foundation (SAO-FRA), agreement between Institute Born-Bunge and University of Antwerp,  
1058 the Medical Research Foundation Antwerp, the Thomas Riellaerts research fund, the  
1059 Alzheimer Research Center Groningen (UMCG) and Neurosearch Antwerp.

1060



1061 **Author Disclosure Statement**

1062 No competing financial interests exist.

1063

1064 **References**

- 1065 1. Roozenbeek, B., Maas, A.I. and Menon, D.K. (2013). Changing patterns in the  
1066 epidemiology of traumatic brain injury. *Nat Rev Neurol* 9, 231-236.
- 1067 2. Bramlett, H.M. and Dietrich, W.D. (2015). Long-Term Consequences of Traumatic  
1068 Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological  
1069 Outcomes. *J Neurotrauma* 32, 1834-1848.
- 1070 3. Collaborators, M.C.T., Perel, P., Arango, M., Clayton, T., Edwards, P., Komolafe, E.,  
1071 Poccock, S., Roberts, I., Shakur, H., Steyerberg, E. and Yutthakasemsunt, S. (2008).  
1072 Predicting outcome after traumatic brain injury: practical prognostic models based on  
1073 large cohort of international patients. *BMJ* 336, 425-429.
- 1074 4. Steyerberg, E.W., Mushkudiani, N., Perel, P., Butcher, I., Lu, J., McHugh, G.S., Murray,  
1075 G.D., Marmarou, A., Roberts, I., Habbema, J.D. and Maas, A.I. (2008). Predicting outcome  
1076 after traumatic brain injury: development and international validation of prognostic  
1077 scores based on admission characteristics. *PLoS Med* 5, e165; discussion e165.
- 1078 5. Maas, A.I., Marmarou, A., Murray, G.D., Teasdale, S.G. and Steyerberg, E.W. (2007).  
1079 Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. *J*  
1080 *Neurotrauma* 24, 232-238.
- 1081 6. Young, N.H. and Andrews, P.J. (2008). Developing a prognostic model for traumatic  
1082 brain injury--a missed opportunity? *PLoS Med* 5, e168.
- 1083 7. Webster, K.M., Sun, M., Crack, P., O'Brien, T.J., Shultz, S.R. and Semple, B.D. (2017).  
1084 Inflammation in epileptogenesis after traumatic brain injury. *J Neuroinflammation* 14,  
1085 10.
- 1086 8. Russo, M.V. and McGavern, D.B. (2016). Inflammatory neuroprotection following  
1087 traumatic brain injury. *Science* 353, 783-785.
- 1088 9. James, M.L., Wang, H., Cantillana, V., Lei, B., Kernagis, D.N., Dawson, H.N., Klamann, L.D.  
1089 and Laskowitz, D.T. (2012). TT-301 inhibits microglial activation and improves outcome  
1090 after central nervous system injury in adult mice. *Anesthesiology* 116, 1299-1311.
- 1091 10. Clausen, F., Hanell, A., Bjork, M., Hillered, L., Mir, A.K., Gram, H. and Marklund, N.  
1092 (2009). Neutralization of interleukin-1beta modifies the inflammatory response and  
1093 improves histological and cognitive outcome following traumatic brain injury in mice.  
1094 *Eur J Neurosci* 30, 385-396.
- 1095 11. Lloyd, E., Somera-Molina, K., Van Eldik, L.J., Watterson, D.M. and Wainwright, M.S.  
1096 (2008). Suppression of acute proinflammatory cytokine and chemokine upregulation by  
1097 post-injury administration of a novel small molecule improves long-term neurologic  
1098 outcome in a mouse model of traumatic brain injury. *J Neuroinflammation* 5, 28.
- 1099 12. Juengst, S.B., Kumar, R.G., Failla, M.D., Goyal, A. and Wagner, A.K. (2015). Acute  
1100 inflammatory biomarker profiles predict depression risk following moderate to severe  
1101 traumatic brain injury. *J Head Trauma Rehabil* 30, 207-218.
- 1102 13. Witcher, K.G., Eiferman, D.S. and Godbout, J.P. (2015). Priming the inflammatory  
1103 pump of the CNS after traumatic brain injury. *Trends Neurosci* 38, 609-620.
- 1104 14. Fenn, A.M., Gensel, J.C., Huang, Y., Popovich, P.G., Lifshitz, J. and Godbout, J.P. (2014).  
1105 Immune activation promotes depression 1 month after diffuse brain injury: a role for  
1106 primed microglia. *Biol Psychiatry* 76, 575-584.
- 1107 15. Bertoglio, D., Verhaeghe, J., Santermans, E., Amhaoul, H., Jonckers, E., Wyffels, L., Van  
1108 Der Linden, A., Hens, N., Staelens, S. and Dedeurwaerdere, S. (2017). Non-invasive PET  
1109 imaging of brain inflammation at disease onset predicts spontaneous recurrent seizures  
1110 and reflects comorbidities. *Brain Behav Immun* 61, 69-79.

- 1111 16. Wang, Y., Yue, X., Kiesewetter, D.O., Niu, G., Teng, G. and Chen, X. (2014). PET imaging  
1112 of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO  
1113 ligand DPA-714. *Eur J Nucl Med Mol Imaging* 41, 1440-1449.
- 1114 17. Yu, I., Inaji, M., Maeda, J., Okauchi, T., Nariai, T., Ohno, K., Higuchi, M. and Suhara, T.  
1115 (2010). Glial cell-mediated deterioration and repair of the nervous system after  
1116 traumatic brain injury in a rat model as assessed by positron emission tomography. *J*  
1117 *Neurotrauma* 27, 1463-1475.
- 1118 18. Roncaroli, F., Su, Z., Herholz, K., Gerhard, A. and Turkheimer, F.E. (2016). TSPO  
1119 expression in brain tumours: is TSPO a target for brain tumour imaging? *Clin Transl*  
1120 *Imaging* 4, 145-156.
- 1121 19. Donat, C.K., Gaber, K., Meixensberger, J., Brust, P., Pinborg, L.H., Hansen, H.H. and  
1122 Mikkelsen, J.D. (2016). Changes in Binding of [(123)I]CLINDE, a High-Affinity  
1123 Translocator Protein 18 kDa (TSPO) Selective Radioligand in a Rat Model of Traumatic  
1124 Brain Injury. *Neuromolecular Med* 18, 158-169.
- 1125 20. Irimia, A., Wang, B., Aylward, S.R., Prastawa, M.W., Pace, D.F., Gerig, G., Hovda, D.A.,  
1126 Kikinis, R., Vespa, P.M. and Van Horn, J.D. (2012). Neuroimaging of structural pathology  
1127 and connectomics in traumatic brain injury: Toward personalized outcome prediction.  
1128 *Neuroimage Clin* 1, 1-17.
- 1129 21. Koerte, I.K., Hufschmidt, J., Muehlmann, M., Lin, A.P. and Shenton, M.E. (2016).  
1130 Advanced Neuroimaging of Mild Traumatic Brain Injury. In: *Translational Research in*  
1131 *Traumatic Brain Injury*. Laskowitz, D., Grant, G. (eds): Boca Raton (FL).
- 1132 22. Wright, D.K., Johnston, L.A., Kershaw, J., Ordidge, R., O'Brien, T.J. and Shultz, S.R.  
1133 (2017). Changes in Apparent Fiber Density and Track-Weighted Imaging Metrics in  
1134 White Matter following Experimental Traumatic Brain Injury. *J Neurotrauma* 34, 2109-  
1135 2118.
- 1136 23. Wright, D.K., Trezise, J., Kamnaksh, A., Bekdash, R., Johnston, L.A., Ordidge, R.,  
1137 Semple, B.D., Gardner, A.J., Stanwell, P., O'Brien, T.J., Agoston, D.V. and Shultz, S.R.  
1138 (2016). Behavioral, blood, and magnetic resonance imaging biomarkers of experimental  
1139 mild traumatic brain injury. *Sci Rep* 6, 28713.
- 1140 24. Kharatishvili, I., Immonen, R., Grohn, O. and Pitkanen, A. (2007). Quantitative  
1141 diffusion MRI of hippocampus as a surrogate marker for post-traumatic epileptogenesis.  
1142 *Brain* 130, 3155-3168.
- 1143 25. Immonen, R., Kharatishvili, I., Grohn, O. and Pitkanen, A. (2013). MRI biomarkers for  
1144 post-traumatic epileptogenesis. *J Neurotrauma* 30, 1305-1309.
- 1145 26. Immonen, R.J., Kharatishvili, I., Grohn, H., Pitkanen, A. and Grohn, O.H. (2009).  
1146 Quantitative MRI predicts long-term structural and functional outcome after  
1147 experimental traumatic brain injury. *Neuroimage* 45, 1-9.
- 1148 27. Frey, L., Lepkin, A., Schickedanz, A., Huber, K., Brown, M.S. and Serkova, N. (2014).  
1149 ADC mapping and T1-weighted signal changes on post-injury MRI predict seizure  
1150 susceptibility after experimental traumatic brain injury. *Neurol Res* 36, 26-37.
- 1151 28. Chastain, C.A., Oyoyo, U.E., Zipperman, M., Joo, E., Ashwal, S., Shutter, L.A. and Tong,  
1152 K.A. (2009). Predicting outcomes of traumatic brain injury by imaging modality and  
1153 injury distribution. *J Neurotrauma* 26, 1183-1196.
- 1154 29. Missault, S., Peeters, L., Amhaoul, H., Thomae, D., Van Eetveldt, A., Favier, B., Thakur,  
1155 A., Van Soom, J., Pitkanen, A., Augustyns, K., Joossens, J., Staelens, S. and  
1156 Dedeurwaerdere, S. (2017). Decreased levels of active uPA and KLK8 assessed by [111  
1157 In]MICA-401 binding correlate with the seizure burden in an animal model of temporal  
1158 lobe epilepsy. *Epilepsia*.

1159 30. Cole, J.T., Yarnell, A., Kean, W.S., Gold, E., Lewis, B., Ren, M., McMullen, D.C.,  
1160 Jacobowitz, D.M., Pollard, H.B., O'Neill, J.T., Grunberg, N.E., Dalgard, C.L., Frank, J.A. and  
1161 Watson, W.D. (2011). Craniotomy: true sham for traumatic brain injury, or a sham of a  
1162 sham? *J Neurotrauma* 28, 359-369.

1163 31. Bourdier, T., Pham, T.Q., Henderson, D., Jackson, T., Lam, P., Izard, M. and Katsifis, A.  
1164 (2012). Automated radiosynthesis of [<sup>18</sup>F]PBR111 and [<sup>18</sup>F]PBR102 using the  
1165 Tracerlab FxFN and Tracerlab MXFDG module for imaging the peripheral  
1166 benzodiazepine receptor with PET. *Appl Radiat Isot* 70, 176-183.

1167 32. Katsifis, A., Loc'h, C., Henderson, D., Bourdier, T., Pham, T., Greguric, I., Lam, P.,  
1168 Callaghan, P., Mattner, F., Eberl, S. and Fulham, M. (2011). A rapid solid-phase extraction  
1169 method for measurement of non-metabolised peripheral benzodiazepine receptor  
1170 ligands, [(18)F]PBR102 and [(18)F]PBR111, in rat and primate plasma. *Nucl Med Biol*  
1171 38, 137-148.

1172 33. Hudson, H.M. and Larkin, R.S. (1994). Accelerated image reconstruction using  
1173 ordered subsets of projection data. *IEEE Trans Med Imaging* 13, 601-609.

1174 34. Defrise, M., Kinahan, P.E., Townsend, D.W., Michel, C., Sibomana, M. and Newport,  
1175 D.F. (1997). Exact and approximate rebinning algorithms for 3-D PET data. *IEEE Trans*  
1176 *Med Imaging* 16, 145-158.

1177 35. Tu, T.W., Turtzo, L.C., Williams, R.A., Lescher, J.D., Dean, D.D. and Frank, J.A. (2014).  
1178 Imaging of spontaneous ventriculomegaly and vascular malformations in Wistar rats:  
1179 implications for preclinical research. *J Neuropathol Exp Neurol* 73, 1152-1165.

1180 36. Missault, S., Van den Eynde, K., Vanden Berghe, W., Franssen, E., Weeren, A.,  
1181 Timmermans, J.P., Kumar-Singh, S. and Dedeurwaerdere, S. (2014). The risk for  
1182 behavioural deficits is determined by the maternal immune response to prenatal  
1183 immune challenge in a neurodevelopmental model. *Brain Behav Immun* 42, 138-146.

1184 37. Amhaoul, H., Hamaide, J., Bertoglio, D., Reichel, S.N., Verhaeghe, J., Geerts, E., Van  
1185 Dam, D., De Deyn, P.P., Kumar-Singh, S., Katsifis, A., Van Der Linden, A., Staelens, S. and  
1186 Dedeurwaerdere, S. (2015). Brain inflammation in a chronic epilepsy model: Evolving  
1187 pattern of the translocator protein during epileptogenesis. *Neurobiol Dis* 82, 526-539.

1188 38. Amhaoul, H., Ali, I., Mola, M., Van Eetveldt, A., Szewczyk, K., Missault, S., Bielen, K.,  
1189 Kumar-Singh, S., Rech, J., Lord, B., Ceusters, M., Bhattacharya, A. and Dedeurwaerdere, S.  
1190 (2016). P2X7 receptor antagonism reduces the severity of spontaneous seizures in a  
1191 chronic model of temporal lobe epilepsy. *Neuropharmacology* 105, 175-185.

1192 39. Fisher, R.S. (2015). Redefining epilepsy. *Curr Opin Neurol* 28, 130-135.

1193 40. Huusko, N., Romer, C., Ndode-Ekane, X.E., Lukasiuk, K. and Pitkanen, A. (2015). Loss  
1194 of hippocampal interneurons and epileptogenesis: a comparison of two animal models  
1195 of acquired epilepsy. *Brain Struct Funct* 220, 153-191.

1196 41. van der Werf, I.M., Van Dam, D., Missault, S., Yalcin, B., De Deyn, P.P., Vandeweyer, G.  
1197 and Kooy, R.F. (2017). Behavioural characterization of AnkyrinG deficient mice, a model  
1198 for ANK3 related disorders. *Behav Brain Res* 328, 218-226.

1199 42. Van den Eynde, K., Missault, S., Franssen, E., Raeymaekers, L., Willems, R.,  
1200 Drinkenburg, W., Timmermans, J.P., Kumar-Singh, S. and Dedeurwaerdere, S. (2014).  
1201 Hypolocomotive behaviour associated with increased microglia in a prenatal immune  
1202 activation model with relevance to schizophrenia. *Behav Brain Res* 258, 179-186.

1203 43. Mizrahi, R., Rusjan, P.M., Kennedy, J., Pollock, B., Mulsant, B., Suridjan, I., De Luca, V.,  
1204 Wilson, A.A. and Houle, S. (2012). Translocator protein (18 kDa) polymorphism  
1205 (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. *J*  
1206 *Cereb Blood Flow Metab* 32, 968-972.

1207 44. Owen, D.R., Yeo, A.J., Gunn, R.N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C.,  
1208 Pulford, D.J., Bennacef, I., Parker, C.A., StJean, P.L., Cardon, L.R., Mooser, V.E., Matthews,  
1209 P.M., Rabiner, E.A. and Rubio, J.P. (2012). An 18-kDa translocator protein (TSPO)  
1210 polymorphism explains differences in binding affinity of the PET radioligand PBR28. *J*  
1211 *Cereb Blood Flow Metab* 32, 1-5.

1212 45. Albrecht, D.S., Granziera, C., Hooker, J.M. and Loggia, M.L. (2016). In Vivo Imaging of  
1213 Human Neuroinflammation. *ACS Chem Neurosci* 7, 470-483.

1214 46. Lyoo, C.H., Ikawa, M., Liow, J.S., Zoghbi, S.S., Morse, C.L., Pike, V.W., Fujita, M., Innis,  
1215 R.B. and Kreisl, W.C. (2015). Cerebellum Can Serve As a Pseudo-Reference Region in  
1216 Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand  
1217 Binding to Translocator Protein. *J Nucl Med* 56, 701-706.

1218 47. Hutchinson, E.B., Schwerin, S.C., Avram, A.V., Juliano, S.L. and Pierpaoli, C. (2017).  
1219 Diffusion MRI and the detection of alterations following traumatic brain injury. *J*  
1220 *Neurosci Res*.

1221 48. Johnstone, V.P., Wright, D.K., Wong, K., O'Brien, T.J., Rajan, R. and Shultz, S.R. (2015).  
1222 Experimental Traumatic Brain Injury Results in Long-Term Recovery of Functional  
1223 Responsiveness in Sensory Cortex but Persisting Structural Changes and Sensorimotor,  
1224 Cognitive, and Emotional Deficits. *J Neurotrauma* 32, 1333-1346.

1225 49. Budde, M.D., Janes, L., Gold, E., Turtzo, L.C. and Frank, J.A. (2011). The contribution of  
1226 gliosis to diffusion tensor anisotropy and tractography following traumatic brain injury:  
1227 validation in the rat using Fourier analysis of stained tissue sections. *Brain* 134, 2248-  
1228 2260.

1229 50. Immonen, R.J., Kharatishvili, I., Niskanen, J.P., Grohn, H., Pitkanen, A. and Grohn, O.H.  
1230 (2009). Distinct MRI pattern in lesional and perilesional area after traumatic brain  
1231 injury in rat--11 months follow-up. *Exp Neurol* 215, 29-40.

1232 51. Kocka, A. and Gagnon, J. (2014). Definition of Impulsivity and Related Terms  
1233 Following Traumatic Brain Injury: A Review of the Different Concepts and Measures  
1234 Used to Assess Impulsivity, Disinhibition and other Related Concepts. *Behav Sci (Basel)*  
1235 4, 352-370.

1236 52. Vonder Haar, C., Martens, K.M., Riparip, L.K., Rosi, S., Wellington, C.L. and  
1237 Winstanley, C.A. (2017). Frontal Traumatic Brain Injury Increases Impulsive Decision  
1238 Making in Rats: A Potential Role for the Inflammatory Cytokine Interleukin-12. *J*  
1239 *Neurotrauma*.

1240 53. Tucker, L.B., Burke, J.F., Fu, A.H. and McCabe, J.T. (2017). Neuropsychiatric Symptom  
1241 Modeling in Male and Female C57BL/6J Mice after Experimental Traumatic Brain  
1242 Injury. *J Neurotrauma* 34, 890-905.

1243 54. Jones, N.C., Cardamone, L., Williams, J.P., Salzberg, M.R., Myers, D. and O'Brien, T.J.  
1244 (2008). Experimental traumatic brain injury induces a pervasive hyperanxious  
1245 phenotype in rats. *J Neurotrauma* 25, 1367-1374.

1246 55. Kim, H., Yu, T., Cam-Etoz, B., van Groen, T., Hubbard, W.J. and Chaudry, I.H. (2017).  
1247 Treatment of traumatic brain injury with 17alpha-ethinylestradiol-3-sulfate in a rat  
1248 model. *J Neurosurg* 127, 23-31.

1249 56. McNamara, K.C., Lisembee, A.M. and Lifshitz, J. (2010). The whisker nuisance task  
1250 identifies a late-onset, persistent sensory sensitivity in diffuse brain-injured rats. *J*  
1251 *Neurotrauma* 27, 695-706.

1252 57. Rowe, R.K., Ziebell, J.M., Harrison, J.L., Law, L.M., Adelson, P.D. and Lifshitz, J. (2016).  
1253 Aging with Traumatic Brain Injury: Effects of Age at Injury on Behavioral Outcome  
1254 following Diffuse Brain Injury in Rats. *Dev Neurosci* 38, 195-205.

- 1255 58. Kelly, K.M. (2004). Spike-wave discharges: absence or not, a common finding in  
1256 common laboratory rats. *Epilepsy Curr* 4, 176-177.
- 1257 59. Pearce, P.S., Friedman, D., Lafrancois, J.J., Iyengar, S.S., Fenton, A.A., Maclusky, N.J.  
1258 and Scharfman, H.E. (2014). Spike-wave discharges in adult Sprague-Dawley rats and  
1259 their implications for animal models of temporal lobe epilepsy. *Epilepsy Behav* 32, 121-  
1260 131.
- 1261 60. Shaw, F.Z. (2004). Is spontaneous high-voltage rhythmic spike discharge in Long  
1262 Evans rats an absence-like seizure activity? *J Neurophysiol* 91, 63-77.
- 1263 61. Rodgers, K.M., Dudek, F.E. and Barth, D.S. (2015). Progressive, Seizure-Like, Spike-  
1264 Wave Discharges Are Common in Both Injured and Uninjured Sprague-Dawley Rats:  
1265 Implications for the Fluid Percussion Injury Model of Post-Traumatic Epilepsy. *J*  
1266 *Neurosci* 35, 9194-9204.
- 1267 62. Sick, T., Wasserman, J., Bregy, A., Sick, J., Dietrich, W.D. and Bramlett, H.M. (2017).  
1268 Increased Expression of Epileptiform Spike/Wave Discharges One Year after Mild,  
1269 Moderate, or Severe Fluid Percussion Brain Injury in Rats. *J Neurotrauma* 34, 2467-  
1270 2474.
- 1271 63. Kelly, K.M., Miller, E.R., Lepsveridze, E., Kharlamov, E.A. and McHedlishvili, Z. (2015).  
1272 Posttraumatic seizures and epilepsy in adult rats after controlled cortical impact.  
1273 *Epilepsy Res* 117, 104-116.
- 1274 64. Bolkvadze, T. and Pitkanen, A. (2012). Development of post-traumatic epilepsy after  
1275 controlled cortical impact and lateral fluid-percussion-induced brain injury in the  
1276 mouse. *J Neurotrauma* 29, 789-812.
- 1277 65. Hunt, R.F., Scheff, S.W. and Smith, B.N. (2009). Posttraumatic epilepsy after  
1278 controlled cortical impact injury in mice. *Exp Neurol* 215, 243-252.
- 1279 66. Hunt, R.F., Scheff, S.W. and Smith, B.N. (2010). Regionally localized recurrent  
1280 excitation in the dentate gyrus of a cortical contusion model of posttraumatic epilepsy. *J*  
1281 *Neurophysiol* 103, 1490-1500.
- 1282 67. Nissinen, J., Andrade, P., Natunen, T., Hiltunen, M., Malm, T., Kanninen, K., Soares, J.I.,  
1283 Shatillo, O., Sallinen, J., Ndode-Ekane, X.E. and Pitkanen, A. (2017). Disease-modifying  
1284 effect of atipamezole in a model of post-traumatic epilepsy. *Epilepsy Res* 136, 18-34.
- 1285 68. Hamm, R.J., Dixon, C.E., Gbadebo, D.M., Singha, A.K., Jenkins, L.W., Lyeth, B.G. and  
1286 Hayes, R.L. (1992). Cognitive deficits following traumatic brain injury produced by  
1287 controlled cortical impact. *J Neurotrauma* 9, 11-20.
- 1288 69. Scheff, S.W., Baldwin, S.A., Brown, R.W. and Kraemer, P.J. (1997). Morris water maze  
1289 deficits in rats following traumatic brain injury: lateral controlled cortical impact. *J*  
1290 *Neurotrauma* 14, 615-627.
- 1291 70. Smith, D.H., Okiyama, K., Thomas, M.J., Claussen, B. and McIntosh, T.K. (1991).  
1292 Evaluation of memory dysfunction following experimental brain injury using the Morris  
1293 water maze. *J Neurotrauma* 8, 259-269.
- 1294 71. Whiting, M.D., Baranova, A.I. and Hamm, R.J. (2006). Cognitive Impairment following  
1295 Traumatic Brain Injury. In: *Animal Models of Cognitive Impairment*. Levin, E.D.,  
1296 Buccafusco, J.J. (eds): Boca Raton (FL).
- 1297 72. Li, L., Wang, W., Zhang, L.M., Jiang, X.Y., Sun, S.Z., Sun, L.J., Guo, Y., Gong, J., Zhang, Y.Z.,  
1298 Wang, H.L. and Li, Y.F. (2017). Overexpression of the 18 kDa translocator protein  
1299 (TSPO) in the hippocampal dentate gyrus produced anxiolytic and antidepressant-like  
1300 behavioural effects. *Neuropharmacology* 125, 117-128.
- 1301 73. Wang, S., Chopp, M., Nazem-Zadeh, M.R., Ding, G., Nejad-Davarani, S.P., Qu, C., Lu, M.,  
1302 Li, L., Davoodi-Bojd, E., Hu, J., Li, Q., Mahmood, A. and Jiang, Q. (2013). Comparison of  
1303 neurite density measured by MRI and histology after TBI. *PLoS One* 8, e63511.

- 1304 74. Save, E. and Moghaddam, M. (1996). Effects of lesions of the associative parietal  
1305 cortex on the acquisition and use of spatial memory in egocentric and allocentric  
1306 navigation tasks in the rat. *Behav Neurosci* 110, 74-85.
- 1307 75. Ikegaya, Y., Nishiyama, N. and Matsuki, N. (2000). L-type Ca(2+) channel blocker  
1308 inhibits mossy fiber sprouting and cognitive deficits following pilocarpine seizures in  
1309 immature mice. *Neuroscience* 98, 647-659.
- 1310 76. Shultz, S.R., Cardamone, L., Liu, Y.R., Hogan, R.E., Maccotta, L., Wright, D.K., Zheng, P.,  
1311 Koe, A., Gregoire, M.C., Williams, J.P., Hicks, R.J., Jones, N.C., Myers, D.E., O'Brien, T.J. and  
1312 Bouillere, V. (2013). Can structural or functional changes following traumatic brain  
1313 injury in the rat predict epileptic outcome? *Epilepsia* 54, 1240-1250.
- 1314